Micro talks stocks

HCV Viral Titer Question

2006-07-11T07:01:00.000-07:00

Chart that was shared at the ASM and probably at ICAR. Source: Avi Biopharma web site shortly after the ASM.

Dr. Burger seemed to indicate some difference in the treatment of the responders versus the non responders in response to a question I asked about only 10 days of treatment for the non responders. But I am certain of what he meant or agreed to. This has been discussed on the Yahoo board.

I accept voicemail's and faxes at 206-339-3785. Never take live calls there and no caller ID. Emails at themicrokid@yahoo.com. If you want me to publish something faxed to me, please let me know. Also let me know how you want it attributed. Anonymous is a favorite of some. Of course I reserve the right to not publish anything.

You are responsible for your own investment decisions!

A couple charts on impact of PR's

2006-06-29T10:21:00.000-07:00

Thanks! Sold the little swing tad, I bought yesterday. Bought it back today at 3.56 two days in a row at 10:42 am. Probably will sell it again today when the shorts decide not to take their position home. Not touching my core long position.

I accept voicemail's and faxes at 206-339-3785. Never take live calls there and no caller ID. Emails at themicrokid@yahoo.com. If you want me to publish something faxed to me, please let me know. Also let me know how you want it attributed. Anonymous is a favorite of some. Of course I reserve the right to not publish anything.

You are responsible for your own investment decisions!

Of course PR's are not the only drivers of share price. But it is pretty clear to me that they are one factor that has at least a short term impact. Long term the impact has to come from getting the science to the market place!

Date	*	Gain Day 1	*	Gain Day 5	*	PR
19-Jan-05		103%		38%		6 days January 19, 2005, Portland, Oregon AVI BioPharma Receives Key U.S. Patents Covering Preservation and Expansion of Stem Cells Using Third-Generation NeuGene Antisense
19-Mar-03		47%		40%		1 days March 19, 2003, Portland, Oregon Avi BioPharma Reports Update of NeuGene Antisense Clinical Development Program for 2002, Plans for 2003
10-May-06		-33%		-39%		14 days May 10, 2006, Portland, Oregon AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting
20-Jan-06		29%		25%		7 days January 20, 2006, Portland, Oregon AVI BioPharma Reports Confirmation of Efficacy Against Influenza Strains
25-Oct-05		25%		10%		23 days October 25, 2005, Portland, Oregon Results From AVI BioPharma’s Antiviral Program Published in Two Virology Journals
14-Oct-05		24%		17%		5 days October 14, 2005, Portland, Oregon AVI BioPharma Updates Results From Department of Defense Funded Collaborative Programs
24-Jun-04		21%		19%		6 days June 24, 2004, Portland, Oregon U.S. Senate Committee on Appropriations Directs $10 Million For Defense-Related Research to AVI BioPharma
13-Jan-06		16%		64%		7 days January 13, 2006, Portland, Oregon AVI BioPharma’s NeuGene Shows Success Against Deadly Ebola Virus
30-Mar-06		16%		8%		21 days March 30, 2006, Portland, Oregon AVI BioPharma Reports Successful Inhibition of Multiple Subtypes of Influenza A Using NeuGene Antisense Therapeutic
28-Apr-03		-14%		-23%		1 days April 28, 2003, Portland, Oregon Avi BioPharma Announces Preclinical Testing Plan For SARS Antisense Compound
1-Apr-04		14%		18%		4 days April 1, 2004, Portland, Oregon AVI BioPharma Reports Anti-Cancer Effects and Single-Dose Bioavailability With NeuGene Antisense Compounds
25-Jun-02		-12%		-17%		16 days June 25, 2002, Portland, Oregon Avi BioPharma NeuGene Antisense Study Featured In Drug Metabolism and Disposition
10-Jan-06		11%		49%		3 days January 10, 2006, Portland, Oregon AVI BioPharma Reports Favorable Safety and Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus
20-Nov-02		11%		11%		15 days November 20, 2002, Portland, Oregon Clinical Trial Supports Further Study of AVI's NeuGene Antisense In Polycystic Kidney Disease Patients
22-Mar-04		-9%		-10%		10 days March 22, 2004, Portland, Oregon AVI BioPharma Announces Additions to Board of Directors
14-May-02		9%		10%		1 days May 14, 2002, Portland, Oregon Avi BioPharma Scientists Publish Results of Antisense Drug In Treating Cancer and Viral Infections
29-Oct-04		9%		0%		3 days October 29, 2004, Portland, Oregon AVI BioPharma NeuGene Antisense Drugs Suppress Influenza A Virus
4-Dec-03		-9%		-19%		6 days December 4, 2003, Portland, Oregon AVI BioPharma Antisense Drug Successfully Treats Feline Viral Outbreak
12-Feb-02		8%		-6%		20 days February 12, 2002, Portland, Oregon Avi BioPharma Obtains Worldwide Exclusive Rights To Important Viral Target
7-May-02		-8%		-17%		3 days May 7, 2002, Portland, Oregon Avi BioPharma Announces Clinical Study Results Providing the First Definitive Evidence of Antisense Efficacy in Humans
24-Apr-03		8%		32%		4 days April 24, 2003, Portland, Oregon Avi BioPharma Completes West Nile Virus Preclinical Development Program
13-Mar-06		8%		-1%		17 days March 13, 2006, Portland, Oregon AVI BioPharma and Cook Group Enter Into License Agreement to Develop NeuGene Drugs for Vascular Diseases
9-May-06		8%		-32%		1 days May 9, 2006, Portland, Oregon AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza
6-Oct-04		8%		2%		23 days October 6, 2004, Portland, Oregon Written Testimony of Alan P. Timmins: BioShield II: Responding to An Ever-Changing Threat
18-Sep-03		8%		3%		20 days September 18, 2003, Portland, Oregon AVI BioPharma Reports Positive Phase II Clinical Results in Restenosis
29-Apr-03		-8%		-9%		7 days April 29, 2003, Portland, Oregon Avi BioPharma Announces Presentation on Antiviral Antisense Program
4-Jan-06		7%		33%		6 days January 4, 2006, Portland, Oregon Increased Defense–Related Funding of AVI BioPharma Approved
10-Nov-04		7%		2%		28 days November 10, 2004, Portland, Oregon AVI BioPharma Reports Final Results From Resten-NG AVAIL Clinical Trial and Updates Its Cardiovascular Restenosis Program
12-Apr-05		7%		1%		8 days April 12, 2005, Portland, Oregon AVI BioPharma Announces Positive Results in NeuGene® Antisense Studies With Collaborators Targeting Emerging Viral Diseases
25-Jan-05		7%		0%		42 days January 25, 2005, Portland, Oregon AVI BioPharma Updates Progress on Infectious Disease Program Using NeuGene Antisense Drugs For RNA Viruses
19-Nov-02		7%		21%		1 days November 19, 2002, Portland, Oregon Studies Support Targeted Systemic Delivery of NeuGene Antisense To Treat Coronary Arteries
10-Aug-04		7%		12%		13 days August 10, 2004, Portland, Oregon AVI BioPharma Announces NeuGene Antisense Collaboration With USAMRIID on Biodefense Agents
17-Nov-05		6%		2%		48 days November 17, 2005, Portland, Oregon AVI BioPharma Strengthens Scientific Advisory Board to Address Infectious Disease and Avian Influenza
8-Mar-05		-6%		-1%		22 days March 8, 2005, Portland, Oregon AVI BioPharma Announces New Board Member Appointments
22-Jul-03		-6%		-10%		7 days July 22, 2003, Portland, Oregon Avi BioPharma Publishes Prostate Cancer Results
21-May-02		-6%		-23%		30 days May 21, 2002, Portland, Oregon Avi BioPharma to Present Avicine Pancreatic Cancer Survival Data At American Society of Clinical Oncology
11-Aug-03		-5%		-7%		3 days August 11, 2003, Portland, Oregon Avi BioPharma Announces Increase in Exchange Ratios For eXegenics Capital Stock and Extends Expiration Date to Aug. 29, 2003
29-Oct-02		-5%		-5%		1 days October 29, 2002, Portland, Oregon Study Supports Topical Application of AVI's NeuGene Antisense
22-Jan-03		-5%		-6%		9 days January 22, 2003, Portland, Oregon Avi Presents Data on Oral Delivery of NeuGene Antisense Drugs at Prestigious Scientific Symposium
8-Dec-04		-5%		-3%		13 days December 8, 2004, Portland, Oregon AVI BioPharma Updates Third-Generation NeuGene Antisense Program
3-Oct-05		5%		3%		11 days October 3, 2005, Portland, Oregon AVI BioPharma Included in Initial Defense Funding Allocation
27-Jan-06		5%		18%		13 days January 27, 2006, Portland, Oregon AVI BioPharma Announces Hepatitis C Virus License Agreement With Chiron
23-Jun-03		-5%		-4%		7 days June 23, 2003, Portland, Oregon Gerald Zon Joins AVI BioPharma Scientific Advisory Board
9-Jan-04		5%		1%		17 days January 9, 2004, Portland, Oregon AVI BioPharma Reports Inhibition of SARS Coronavirus With NeuGene Antisense Drugs
10-Dec-03		-5%		-2%		13 days December 10, 2003, Portland, Oregon AVI Presents Preclinical Data on Microbubble Drug Delivery And NeuGene Antisense Anti-Cancer Strategies
21-Mar-02		-5%		-15%		19 days March 21, 2002, Portland, Oregon Avi BioPharma Announces Efficacy of Oral Administration Of Its Proprietary NeuGene Antisense Agents in Rats
20-Apr-06		-4%		-2%		19 days April 20, 2006, Portland, Oregon AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status
8-Jan-04		4%		9%		1 days January 8, 2004, Portland, Oregon AVI BioPharma Bolsters Clinical and Regulatory Expertise
20-Feb-03		4%		-10%		6 days February 20, 2003, Portland, Oregon Avi BioPharma Study Results Reveal Increased Utility for NeuGene Antisense Drug
1-Aug-02		-4%		-11%		61 days August 1, 2002, Portland, Oregon Avi BioPharma Completes NeuGene Antisense Clinical Trial In Patients With Polycystic Kidney Disease
1-Nov-04		4%		-9%		9 days November 1, 2004, Portland, Oregon AVI BioPharma and USAMRIID Announce NeuGene Antisense Drug Demonstrates Efficacy Against Ebola Virus
21-Dec-04		-4%		0%		28 days December 21, 2004, Portland, Oregon AVI BioPharma Announces NeuGene Antisense Collaboration With the Walter Reed Army Institute of Research
6-Jun-05		4%		-1%		3 days June 6, 2005, Portland, Oregon AVI BioPharma Announces Positive Results With Neugene Antisense Drugs at the Endocrine Society Annual Meeting
16-Jul-03		-4%		-13%		6 days July 16, 2003, Portland, Oregon and Dallas, Texas Avi BioPharma to Acquire eXegenics in $11.0 Million Stock Exchange
29-Apr-02		-4%		6%		3 days April 29, 2002, Portland, Oregon Avi BioPharma Initiates Clinical Development Program For NeuGene Antisense Treatment of Coronary Artery Bypass Grafts
20-Sep-05		4%		2%		8 days September 20, 2005, Portland, Oregon AVI BioPharma Initiates Phase II Cardiovascular Clinical Study in Europe
18-Mar-04		4%		-7%		4 days March 18, 2004, Portland, Oregon AVI Reports Positive Clinical Results On Oral Delivery of Its NeuGene Antisense Drug
31-Jan-03		-3%		-22%		20 days January 31, 2003, Portland, Oregon Avi NeuGene Antisense Drug Increases Effectiveness Of Chemotherapy in Treating Lung Cancer #2 Avi Awarded Grant From National Cancer Institute to Target Prostate Cancer with NeuGene Antisense Drugs
21-Oct-05		3%		8%		4 days October 21, 2005, Portland, Oregon AVI BioPharma Provides Update on Influenza Drug Development Program
4-Mar-02		3%		3%		17 days March 4, 2002, Portland, Oregon Avi BioPharma Scientists to Present Novel Antisense Approach For Prostate Cancer and Emerging Infectious Diseases at Conferences Worldwide
6-Nov-03		3%		-6%		5 days November 6, 2003, Portland, Oregon AVI Presents Data on Microbubble Delivery of Restenosis Drug At American Heart Association Annual Meeting
20-Jun-05		-3%		-5%		10 days June 20, 2005, Portland, Oregon AVI BioPharma and Collaborators Announce Positive Results With NeuGene Antisense Drugs at American Society for Virology Annual Meeting
29-Oct-03		-3%		-6%		7 days October 29, 2003, Portland, Oregon AVI BioPharma Updates Progress on Infectious Disease Program Using NeuGene Antisense For RNA Viruses
30-Jul-03		-3%		3%		5 days July 30, 2003, Portland, Oregon Avi BioPharma Updates Progress on Cardiovascular Disease Program With NeuGene Antisense
5-Nov-02		3%		-1%		14 days November 5, 2002, Portland, Oregon Avi BioPharma Initiates New Round of Human Clinical Trials With NeuGene Antisense Targeting Drug Metabolism
9-Jul-03		3%		3%		6 days July 9, 2003, Portland, Oregon Avi BioPharma CEO to Present at International Science Symposium On SARS in China
20-May-04		-3%		3%		12 days May 20, 2004, Portland, Oregon Journal of Virology Publication Highlights Antiviral Activity Of AVI BioPharma’s NeuGene Antisense Compound
20-Mar-03		3%		-2%		6 days March 20, 2003, Portland, Oregon Avi BioPharma Updates Progress in Single Stranded RNA Viruses With NeuGene Antisense Compounds
7-Mar-06		-3%		-2%		6 days March 7, 2006, Portland, Oregon AVI BioPharma Successful Ebola Study Results Highlighted in Nature Reviews Drug Discovery
12-Dec-02		3%		1%		6 days December 12, 2002, Portland, Oregon Avi Presents NeuGene Antisense Data Targeting Prostate Cancer At Scientific Conference #2 Avi BioPharma Completes Clinical Trials With NeuGene Antisense Targeting Drug Metabolism
17-May-02		3%		-6%		3 days May 17, 2002, Portland, Oregon Avi BioPharma to Present Novel Antisense Approach at Leading Interventional Cardiology Conference
19-Jun-03		3%		-6%		1 days June 19, 2003, Portland, Oregon Avi BioPharma Reports Positive Results From NeuGene Cancer Trial
24-Jul-02		3%		21%		8 days July 24, 2002, Portland, Oregon Promising Results of AVI BioPharma Colorectal Study Featured In Clinical Cancer Research
13-Mar-03		3%		28%		6 days March 13, 2003, Portland, Oregon Avi BioPharma Scientist Presents Data Showing Novel Antisense Inhibits Gene Expression of Metabolic Enzyme in Human Liver
15-Jul-03		3%		-5%		1 days July 15, 2003, Portland, Oregon Avi BioPharma Presents Positive Results With its Novel Antisense Drug For Prostate Cancer
26-Mar-03		2%		17%		7 days March 26, 2003, Portland, Oregon Avi BioPharma Advances NeuGene Antisense Cancer Program
9-Feb-06		2%		-5%		26 days February 9, 2006, Portland, Oregon Successful Muscular Dystrophy Treatment Results Using AVI BioPharma Technology Published in Nature Medicine
18-Jan-05		-2%		26%		1 days January 18, 2005, Portland, Oregon AVI BioPharma Appoints Vice President of Cardiology
30-Jun-03		2%		-2%		1 days June 30, 2003, Portland, Oregon Avi BioPharma Files IND With FDA For West Nile Virus NeuGene Antisense Drug
14-May-03		-2%		0%		36 days May 14, 2003, Portland, Oregon Avi Files for Orphan Designation for its West Nile Virus Drug
31-Aug-04		2%		-9%		10 days August 31, 2004, Portland, Oregon AVI BioPharma Announces Initiation of Acute West Nile Virus Clinical Study
5-Jun-06		-2%		-7%		24 days June 5, 2006, Portland, Oregon AVI BioPharma Presents Preclinical Results Preventing and Treating Diabetes Using Its ESPRIT Exon Skipping Technology
6-May-03		-2%		9%		1 days May 6, 2003, Portland, Oregon Avi BioPharma to Testify at House Energy and Commerce SARS Hearing
23-Dec-03		2%		1%		7 days December 23, 2003, Portland, Oregon AVI BioPharma Reports Confirmation of Positive Phase II Clinical Results In Restenosis
30-Dec-03		-2%		-4%		9 days December 30, 2003, Portland, Oregon AVI BioPharma Announces Results From West Nile Virus Clinical Trial
19-Jul-05		2%		-4%		7 days July 19, 2005, Portland, Oregon AVI BioPharma Announces Publication of SARS NeuGene Antisense Studies in the Journal of Virology
10-Oct-03		2%		-5%		19 days October 10, 2003, Portland, Oregon AVI Initiates Clinical Study to Evaluate the Oral Efficacy of Its NeuGene Antisense Drug
17-Nov-03		-2%		-7%		17 days November 17, 2003, Portland, Oregon AVI BioPharma Announces Publication of Prostate Cancer Results
7-May-03		2%		13%		7 days May 7, 2003, Washington D.C. Dr. Denis Burger's Written Testimony from House Energy and Commerce SARS Hearing
15-May-02		2%		-5%		2 days May 15, 2002, Portland, Oregon Avi BioPharma Appoints Andrew J. Ferrara to Board Of Directors
19-Oct-05		-2%		23%		2 days October 19, 2005, Portland, Oregon AVI BioPharma Announces Presentation of Data at Transcatheter Cardiovascular Therapeutics Conference
28-Sep-05		2%		18%		1 days September 28, 2005, Portland, Oregon AVI BioPharma Initiates Hepatitis C Clinical Trial
1-Jun-04		2%		4%		23 days June 1, 2004, Portland, Oregon AVI BioPharma’s NeuGene Antisense Shows Inhibition of Dengue Virus
11-Jul-02		-2%		0%		13 days July 11, 2002, Portland, Oregon Avi BioPharma Demonstrates Effective Delivery of NeuGene Antisense Therapeutics
4-Sep-03		2%		-2%		6 days September 4, 2003, Portland, Oregon AVI Reports Positive Independent Results With NeuGene Antisense Compound Targeting SARS
30-Oct-02		2%		3%		6 days October 30, 2002, Portland, Oregon Avi's Combination Antisense Strategy Inhibits Tumor Growth In Human Prostate Cancer Models
13-Nov-03		-2%		3%		4 days November 13, 2003, Portland, Oregon AVI BioPharma Announces Presentation of Data And Filing for Orphan Designation in Polycystic Kidney Disease
2-May-02		-1%		-17%		5 days May 2, 2002, Portland, Oregon Avi BioPharma Announces Plans to Initiate Phase III Clinical Trial In Pancreatic Cancer With Avicine
20-Apr-05		1%		-3%		47 days April 20, 2005, Portland, Oregon AVI BioPharma Presents Positive Results With NeuGene Antisense Drugs At the American Association for Cancer Research Meeting
26-Jan-04		1%		-8%		52 days January 26, 2004, Portland, Oregon AVI BioPharma Reports Successful NeuGene Antisense Approach To Regulation of the Immune Response in Transplantation
29-Sep-05		-1%		23%		4 days September 29, 2005, Portland, Oregon AVI BioPharma Introduces ESPRIT With Initial Application in Muscular Dystrophy
20-Jun-03		-1%		-5%		3 days June 20, 2003, Portland, Oregon Avi BioPharma Announces Positive Data on New Prostate Cancer Target
18-Dec-02		-1%		4%		35 days December 18, 2002, Portland, Oregon Avi BioPharma and International Therapeutics Enter Research Agreement to Target HIV Virus
1-Jul-03		-1%		-2%		6 days July 1, 2003, Portland, Oregon Avi BioPharma Added to Russell 3000 Index
8-Oct-03		1%		2%		2 days October 8, 2003, Portland, Oregon AVI BioPharma to Initiate Second West Nile Virus Clinical Study With NeuGene Antisense Drug
11-Nov-03		-1%		6%		2 days November 11, 2003, Portland, Oregon AVI BioPharma Presents Antisense Antiviral Technology at SMi Conference
20-Jun-02		1%		-16%		5 days June 20, 2002, Portland, Oregon Avi BioPharma Presents Effectiveness of NeuGene Antisense Agent In Inhibiting Prostate Cancer Cell Growth
23-Aug-04		1%		14%		8 days August 23, 2004, Portland, Oregon AVI BioPharma Announces Dengue Virus Collaboration With CDC
2-Apr-03		-1%		4%		22 days April 2, 2003, Portland, Oregon Avi BioPharma Presents Data on Systemic Delivery of NeuGene Antisense Drug to Treat Cardiovascular Restenosis
14-Aug-03		1%		1%		5 days August 14, 2003, Portland, Oregon Avi Files for Orphan Designation for Its SARS Coronavirus Antisense Drug
30-Jun-05		-1%		-3%		19 days June 30, 2005, Portland, Oregon AVI BioPharma Submits IND for NeuGene Antisense Drug Targeting Hepatitis C Virus
30-Jun-04		-1%		-8%		21 days June 30, 2004, Portland, Oregon AVI BioPharma Announces Termination of Cardiovascular Agreement With Medtronic
4-Aug-03		1%		-1%		7 days August 4, 2003, Portland, Oregon Avi BioPharma Is Cleared to Initiate Clinical Trial for West Nile Virus With NeuGene Antisense Drug
29-Jul-03		-1%		-2%		1 days July 29, 2003, Portland, Oregon and Dallas, Texas Avi BioPharma and eXegenics Announce Commencement of Exchange Offer For eXegenics Common Stock and eXegenics Preferred Stock
1-Oct-02		-1%		4%		23 days October 1, 2002, Portland, Oregon Avi Announces Positive Interim Results of Phase II Antisense Trial For Cardiovascular Restenosis
9-Apr-02		-1%		8%		14 days April 9, 2002, Portland, Oregon Avi BioPharma Scientist Presents Novel Antisense Approach For Prostate Cancer at AACR 93rd Annual Meeting
4-May-04		1%		-13%		16 days May 4, 2004, Portland, Oregon AVI BioPharma Presents Additional Data on West Nile Virus Clinical Trial At International Antiviral Conference
10-May-02		1%		10%		4 days May 10, 2002, Portland, Oregon Avi BioPharma Demonstrates Effectiveness of Antisense Drug In Treating Symptoms of Polycystic Kidney Disease
26-Feb-03		-1%		-13%		15 days February 26, 2003, Portland, Oregon Avi Announces Final Results of NeuGene Antisense Study In Polycystic Kidney Disease Patients
24-Oct-02		-1%		4%		5 days October 24, 2002, Portland, Oregon Avi BioPharma Confirms Availability of Additional Route Of Administration for NeuGene Antisense Drugs
23-Apr-02		-1%		-6%		6 days April 23, 2002, Portland, Oregon Avi BioPharma Scientist Presents Data Showing Novel Antisense Inhibits Gene Expression of Metabolic Enzyme in Human Liver
2-Sep-03		-1%		-3%		2 days September 2, 2003, Portland, Oregon AVI BioPharma Announces Termination of Merger Agreement, Exchange Offer With eXegenics, Inc.
21-Jul-04		0%		-7%		20 days July 21, 2004, Portland, Oregon AVI BioPharma Receives Notice of Allowance for Key Patent Application Covering NeuGene Antisense Technology for RNA Viruses
19-Aug-03		0%		8%		14 days August 19, 2003, Portland, Oregon Avi Begins Phase II Study of Systemic Delivery Of Resten-NG in Restenosis
24-May-06		0%		-2%		12 days May 24, 2006, Portland, Oregon AVI BioPharma Receives Notice of Allowance for a Patent Application Covering the Use of NeuGene Antisense Technology for the Development of a New Class of Antibiotics
5-Nov-03		0%		-5%		1 days November 5, 2003, Portland, Oregon AVI BioPharma Presents Preclinical Data on Cholesterol-Lowering Program
20-May-02		0%		-10%		1 days May 20, 2002, Portland, Oregon Avi BioPharma Demonstrates Effectiveness of NeuGene Antisense Agents As Potential Antibiotics Targeting Calicivirus and E. Coli
5-Apr-04		0%		3%		29 days April 5, 2004, Portland, Oregon AVI BioPharma Expands Management Team
5-Feb-02		0%		2%		7 days February 5, 2002, Portland, Oregon Avi BioPharma Opens GMP Manufacturing Plant For NeuGene Antisense Drugs for Clinical Trials and Commercialization
5-Dec-02		0%		-9%		7 days December 5, 2002, Portland, Oregon Avi Announces Promising NeuGene Antisense Results Targeting Viruses
10-Sep-03		0%		1%		8 days September 10, 2003, Portland, Oregon AVI BioPharma Begins Clinical Trial of West Nile Virus Patients
7-Jul-03		0%		2%		2 days July 7, 2003, Portland, Oregon Avi BioPharma Manufactures West Nile Virus Antisense Drug
9-Jun-05		0%		6%		11 days June 9, 2005, Portland, Oregon Crossing The Valley Of Death: Bringing Promising Medical Countermeasures To Bioshield Written Testimony of Alan P. Timmins President and Chief Operating Officer AVI Biopharma, #2 Testify before Congress
30-Mar-05		0%		-2%		13 days March 30, 2005, Portland, Oregon AVI BioPharma Announces Publication of West Nile and Dengue Virus NeuGene Antisense Studies in the Journal of Virology
10-Sep-04		0%		7%		26 days September 10, 2004, Portland, Oregon AVI BioPharma Presents Antisense Approach to Transplant Acceptance By Regulating Activated Lymphocytes
26-Jul-05		0%		3%		56 days July 26, 2005, Portland, Oregon AVI BioPharma Reports Continued Success in Preclinical Antiviral Efforts

AVII Press Releases

2006-06-28T08:44:00.000-07:00

These charts explore the days between press releases not including investment conferences, financings, and quarterly/annual results.

The average is 11.5 days and the standard deviation is 11.7 days. Dropping all the 0 and 1 days between from the data set raises the average to 13.8 days This is brought down by the fact that there are a few events that seem to spur multiple releases in a short time.

Tommorrow will make 24 days since a press release.

DAYS BETWEEN ORDER
0 days June 9, 2005, Portland, Oregon AVI BioPharma to Testify Before Congressional Committee on Bioterrorism Research and Development
0 days January 31, 2003, Portland, Oregon Avi Awarded Grant From National Cancer Institute to Target Prostate Cancer with NeuGene Antisense Drugs
0 days December 12, 2002, Portland, Oregon Avi BioPharma Completes Clinical Trials With NeuGene Antisense Targeting Drug Metabolism
1 days May 9, 2006, Portland, Oregon AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza
1 days September 28, 2005, Portland, Oregon AVI BioPharma Initiates Hepatitis C Clinical Trial
1 days January 18, 2005, Portland, Oregon AVI BioPharma Appoints Vice President of Cardiology
1 days January 8, 2004, Portland, Oregon AVI BioPharma Bolsters Clinical and Regulatory Expertise
1 days November 5, 2003, Portland, Oregon AVI BioPharma Presents Preclinical Data on Cholesterol-Lowering Program
1 days July 29, 2003, Portland, Oregon and Dallas, Texas Avi BioPharma and eXegenics Announce Commencement of Exchange Offer For eXegenics Common Stock and eXegenics Preferred Stock
1 days July 15, 2003, Portland, Oregon Avi BioPharma Presents Positive Results With its Novel Antisense Drug For Prostate Cancer
1 days June 30, 2003, Portland, Oregon Avi BioPharma Files IND With FDA For West Nile Virus NeuGene Antisense Drug
1 days June 19, 2003, Portland, Oregon Avi BioPharma Reports Positive Results From NeuGene Cancer Trial
1 days May 6, 2003, Portland, Oregon Avi BioPharma to Testify at House Energy and Commerce SARS Hearing
1 days April 28, 2003, Portland, Oregon Avi BioPharma Announces Preclinical Testing Plan For SARS Antisense Compound
1 days March 19, 2003, Portland, Oregon Avi BioPharma Reports Update of NeuGene Antisense Clinical Development Program for 2002, Plans for 2003
1 days November 19, 2002, Portland, Oregon Studies Support Targeted Systemic Delivery of NeuGene Antisense To Treat Coronary Arteries
1 days October 29, 2002, Portland, Oregon Study Supports Topical Application of AVI's NeuGene Antisense
1 days May 20, 2002, Portland, Oregon Avi BioPharma Demonstrates Effectiveness of NeuGene Antisense Agents As Potential Antibiotics Targeting Calicivirus and E. Coli
1 days May 14, 2002, Portland, Oregon Avi BioPharma Scientists Publish Results of Antisense Drug In Treating Cancer and Viral Infections
2 days October 19, 2005, Portland, Oregon AVI BioPharma Announces Presentation of Data at Transcatheter Cardiovascular Therapeutics Conference
2 days November 11, 2003, Portland, Oregon AVI BioPharma Presents Antisense Antiviral Technology at SMi Conference
2 days October 8, 2003, Portland, Oregon AVI BioPharma to Initiate Second West Nile Virus Clinical Study With NeuGene Antisense Drug
2 days September 2, 2003, Portland, Oregon AVI BioPharma Announces Termination of Merger Agreement, Exchange Offer With eXegenics, Inc.
2 days July 7, 2003, Portland, Oregon Avi BioPharma Manufactures West Nile Virus Antisense Drug
2 days May 15, 2002, Portland, Oregon Avi BioPharma Appoints Andrew J. Ferrara to Board Of Directors
3 days January 10, 2006, Portland, Oregon AVI BioPharma Reports Favorable Safety and Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus
3 days June 6, 2005, Portland, Oregon AVI BioPharma Announces Positive Results With Neugene Antisense Drugs at the Endocrine Society Annual Meeting
3 days October 29, 2004, Portland, Oregon AVI BioPharma NeuGene Antisense Drugs Suppress Influenza A Virus
3 days August 11, 2003, Portland, Oregon Avi BioPharma Announces Increase in Exchange Ratios For eXegenics Capital Stock and Extends Expiration Date to Aug. 29, 2003
3 days June 20, 2003, Portland, Oregon Avi BioPharma Announces Positive Data on New Prostate Cancer Target
3 days May 17, 2002, Portland, Oregon Avi BioPharma to Present Novel Antisense Approach at Leading Interventional Cardiology Conference
3 days May 7, 2002, Portland, Oregon Avi BioPharma Announces Clinical Study Results Providing the First Definitive Evidence of Antisense Efficacy in Humans
3 days April 29, 2002, Portland, Oregon Avi BioPharma Initiates Clinical Development Program For NeuGene Antisense Treatment of Coronary Artery Bypass Grafts
4 days October 21, 2005, Portland, Oregon AVI BioPharma Provides Update on Influenza Drug Development Program
4 days September 29, 2005, Portland, Oregon AVI BioPharma Introduces ESPRIT With Initial Application in Muscular Dystrophy
4 days April 1, 2004, Portland, Oregon AVI BioPharma Reports Anti-Cancer Effects and Single-Dose Bioavailability With NeuGene Antisense Compounds
4 days March 18, 2004, Portland, Oregon AVI Reports Positive Clinical Results On Oral Delivery of Its NeuGene Antisense Drug
4 days November 13, 2003, Portland, Oregon AVI BioPharma Announces Presentation of Data And Filing for Orphan Designation in Polycystic Kidney Disease
4 days April 24, 2003, Portland, Oregon Avi BioPharma Completes West Nile Virus Preclinical Development Program
4 days May 10, 2002, Portland, Oregon Avi BioPharma Demonstrates Effectiveness of Antisense Drug In Treating Symptoms of Polycystic Kidney Disease
5 days October 14, 2005, Portland, Oregon AVI BioPharma Updates Results From Department of Defense Funded Collaborative Programs
5 days November 6, 2003, Portland, Oregon AVI Presents Data on Microbubble Delivery of Restenosis Drug At American Heart Association Annual Meeting
5 days August 14, 2003, Portland, Oregon Avi Files for Orphan Designation for Its SARS Coronavirus Antisense Drug
5 days July 30, 2003, Portland, Oregon Avi BioPharma Updates Progress on Cardiovascular Disease Program With NeuGene Antisense
5 days October 24, 2002, Portland, Oregon Avi BioPharma Confirms Availability of Additional Route Of Administration for NeuGene Antisense Drugs
5 days June 20, 2002, Portland, Oregon Avi BioPharma Presents Effectiveness of NeuGene Antisense Agent In Inhibiting Prostate Cancer Cell Growth
5 days May 2, 2002, Portland, Oregon Avi BioPharma Announces Plans to Initiate Phase III Clinical Trial In Pancreatic Cancer With Avicine
6 days March 7, 2006, Portland, Oregon AVI BioPharma Successful Ebola Study Results Highlighted in Nature Reviews Drug Discovery
6 days January 4, 2006, Portland, Oregon Increased Defense–Related Funding of AVI BioPharma Approved
6 days January 19, 2005, Portland, Oregon AVI BioPharma Receives Key U.S. Patents Covering Preservation and Expansion of Stem Cells Using Third-Generation NeuGene Antisense
6 days June 24, 2004, Portland, Oregon U.S. Senate Committee on Appropriations Directs $10 Million For Defense-Related Research to AVI BioPharma
6 days December 4, 2003, Portland, Oregon AVI BioPharma Antisense Drug Successfully Treats Feline Viral Outbreak
6 days September 4, 2003, Portland, Oregon AVI Reports Positive Independent Results With NeuGene Antisense Compound Targeting SARS
6 days July 16, 2003, Portland, Oregon and Dallas, Texas Avi BioPharma to Acquire eXegenics in $11.0 Million Stock Exchange
6 days July 9, 2003, Portland, Oregon Avi BioPharma CEO to Present at International Science Symposium On SARS in China
6 days July 1, 2003, Portland, Oregon Avi BioPharma Added to Russell 3000 Index
6 days March 20, 2003, Portland, Oregon Avi BioPharma Updates Progress in Single Stranded RNA Viruses With NeuGene Antisense Compounds
6 days March 13, 2003, Portland, Oregon Avi BioPharma Scientist Presents Data Showing Novel Antisense Inhibits Gene Expression of Metabolic Enzyme in Human Liver
6 days February 20, 2003, Portland, Oregon Avi BioPharma Study Results Reveal Increased Utility for NeuGene Antisense Drug
6 days December 12, 2002, Portland, Oregon Avi Presents NeuGene Antisense Data Targeting Prostate Cancer At Scientific Conference
6 days October 30, 2002, Portland, Oregon Avi's Combination Antisense Strategy Inhibits Tumor Growth In Human Prostate Cancer Models
6 days April 23, 2002, Portland, Oregon Avi BioPharma Scientist Presents Data Showing Novel Antisense Inhibits Gene Expression of Metabolic Enzyme in Human Liver
7 days January 20, 2006, Portland, Oregon AVI BioPharma Reports Confirmation of Efficacy Against Influenza Strains
7 days January 13, 2006, Portland, Oregon AVI BioPharma’s NeuGene Shows Success Against Deadly Ebola Virus
7 days July 19, 2005, Portland, Oregon AVI BioPharma Announces Publication of SARS NeuGene Antisense Studies in the Journal of Virology
7 days December 23, 2003, Portland, Oregon AVI BioPharma Reports Confirmation of Positive Phase II Clinical Results In Restenosis
7 days October 29, 2003, Portland, Oregon AVI BioPharma Updates Progress on Infectious Disease Program Using NeuGene Antisense For RNA Viruses
7 days August 4, 2003, Portland, Oregon Avi BioPharma Is Cleared to Initiate Clinical Trial for West Nile Virus With NeuGene Antisense Drug
7 days July 22, 2003, Portland, Oregon Avi BioPharma Publishes Prostate Cancer Results
7 days June 23, 2003, Portland, Oregon Gerald Zon Joins AVI BioPharma Scientific Advisory Board
7 days May 7, 2003, Washington D.C. Dr. Denis Burger's Written Testimony from House Energy and Commerce SARS Hearing
7 days April 29, 2003, Portland, Oregon Avi BioPharma Announces Presentation on Antiviral Antisense Program
7 days March 26, 2003, Portland, Oregon Avi BioPharma Advances NeuGene Antisense Cancer Program
7 days December 5, 2002, Portland, Oregon Avi Announces Promising NeuGene Antisense Results Targeting Viruses
7 days February 5, 2002, Portland, Oregon Avi BioPharma Opens GMP Manufacturing Plant For NeuGene Antisense Drugs for Clinical Trials and Commercialization
8 days September 20, 2005, Portland, Oregon AVI BioPharma Initiates Phase II Cardiovascular Clinical Study in Europe
8 days April 12, 2005, Portland, Oregon AVI BioPharma Announces Positive Results in NeuGene® Antisense Studies With Collaborators Targeting Emerging Viral Diseases
8 days August 23, 2004, Portland, Oregon AVI BioPharma Announces Dengue Virus Collaboration With CDC
8 days September 10, 2003, Portland, Oregon AVI BioPharma Begins Clinical Trial of West Nile Virus Patients
8 days July 24, 2002, Portland, Oregon Promising Results of AVI BioPharma Colorectal Study Featured In Clinical Cancer Research
9 days November 1, 2004, Portland, Oregon AVI BioPharma and USAMRIID Announce NeuGene Antisense Drug Demonstrates Efficacy Against Ebola Virus
9 days December 30, 2003, Portland, Oregon AVI BioPharma Announces Results From West Nile Virus Clinical Trial
9 days January 22, 2003, Portland, Oregon Avi Presents Data on Oral Delivery of NeuGene Antisense Drugs at Prestigious Scientific Symposium
10 days June 20, 2005, Portland, Oregon AVI BioPharma and Collaborators Announce Positive Results With NeuGene Antisense Drugs at American Society for Virology Annual Meeting
10 days August 31, 2004, Portland, Oregon AVI BioPharma Announces Initiation of Acute West Nile Virus Clinical Study
10 days March 22, 2004, Portland, Oregon AVI BioPharma Announces Additions to Board of Directors
11 days October 3, 2005, Portland, Oregon AVI BioPharma Included in Initial Defense Funding Allocation
11 days June 9, 2005, Portland, Oregon Crossing The Valley Of Death: Bringing Promising Medical Countermeasures To Bioshield Written Testimony of Alan P. Timmins President and Chief Operating Officer AVI Biopharma, In
12 days May 24, 2006, Portland, Oregon AVI BioPharma Receives Notice of Allowance for a Patent Application Covering the Use of NeuGene Antisense Technology for the Development of a New Class of Antibiotics
12 days May 20, 2004, Portland, Oregon Journal of Virology Publication Highlights Antiviral Activity Of AVI BioPharma’s NeuGene Antisense Compound
13 days January 27, 2006, Portland, Oregon AVI BioPharma Announces Hepatitis C Virus License Agreement With Chiron
13 days March 30, 2005, Portland, Oregon AVI BioPharma Announces Publication of West Nile and Dengue Virus NeuGene Antisense Studies in the Journal of Virology
13 days December 8, 2004, Portland, Oregon AVI BioPharma Updates Third-Generation NeuGene Antisense Program
13 days August 10, 2004, Portland, Oregon AVI BioPharma Announces NeuGene Antisense Collaboration With USAMRIID on Biodefense Agents
13 days December 10, 2003, Portland, Oregon AVI Presents Preclinical Data on Microbubble Drug Delivery And NeuGene Antisense Anti-Cancer Strategies
13 days July 11, 2002, Portland, Oregon Avi BioPharma Demonstrates Effective Delivery of NeuGene Antisense Therapeutics
14 days May 10, 2006, Portland, Oregon AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting
14 days August 19, 2003, Portland, Oregon Avi Begins Phase II Study of Systemic Delivery Of Resten-NG in Restenosis
14 days November 5, 2002, Portland, Oregon Avi BioPharma Initiates New Round of Human Clinical Trials With NeuGene Antisense Targeting Drug Metabolism
14 days April 9, 2002, Portland, Oregon Avi BioPharma Scientist Presents Novel Antisense Approach For Prostate Cancer at AACR 93rd Annual Meeting
15 days February 26, 2003, Portland, Oregon Avi Announces Final Results of NeuGene Antisense Study In Polycystic Kidney Disease Patients
15 days November 20, 2002, Portland, Oregon Clinical Trial Supports Further Study of AVI's NeuGene Antisense In Polycystic Kidney Disease Patients
16 days May 4, 2004, Portland, Oregon AVI BioPharma Presents Additional Data on West Nile Virus Clinical Trial At International Antiviral Conference
16 days June 25, 2002, Portland, Oregon Avi BioPharma NeuGene Antisense Study Featured In Drug Metabolism and Disposition
17 days March 13, 2006, Portland, Oregon AVI BioPharma and Cook Group Enter Into License Agreement to Develop NeuGene Drugs for Vascular Diseases
17 days January 9, 2004, Portland, Oregon AVI BioPharma Reports Inhibition of SARS Coronavirus With NeuGene Antisense Drugs
17 days November 17, 2003, Portland, Oregon AVI BioPharma Announces Publication of Prostate Cancer Results
17 days March 4, 2002, Portland, Oregon Avi BioPharma Scientists to Present Novel Antisense Approach For Prostate Cancer and Emerging Infectious Diseases at Conferences Worldwide
19 days April 20, 2006, Portland, Oregon AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status
19 days June 30, 2005, Portland, Oregon AVI BioPharma Submits IND for NeuGene Antisense Drug Targeting Hepatitis C Virus
19 days October 10, 2003, Portland, Oregon AVI Initiates Clinical Study to Evaluate the Oral Efficacy of Its NeuGene Antisense Drug
19 days March 21, 2002, Portland, Oregon Avi BioPharma Announces Efficacy of Oral Administration Of Its Proprietary NeuGene Antisense Agents in Rats
20 days July 21, 2004, Portland, Oregon AVI BioPharma Receives Notice of Allowance for Key Patent Application Covering NeuGene Antisense Technology for RNA Viruses
20 days September 18, 2003, Portland, Oregon AVI BioPharma Reports Positive Phase II Clinical Results in Restenosis
20 days January 31, 2003, Portland, Oregon Avi NeuGene Antisense Drug Increases Effectiveness Of Chemotherapy in Treating Lung Cancer
20 days February 12, 2002, Portland, Oregon Avi BioPharma Obtains Worldwide Exclusive Rights To Important Viral Target
21 days June 5, 2006, Portland, Oregon AVI BioPharma Presents Preclinical Results Preventing and Treating Diabetes Using Its ESPRIT Exon Skipping Technology
21 days March 30, 2006, Portland, Oregon AVI BioPharma Reports Successful Inhibition of Multiple Subtypes of Influenza A Using NeuGene Antisense Therapeutic
21 days June 30, 2004, Portland, Oregon AVI BioPharma Announces Termination of Cardiovascular Agreement With Medtronic
22 days March 8, 2005, Portland, Oregon AVI BioPharma Announces New Board Member Appointments
22 days April 2, 2003, Portland, Oregon Avi BioPharma Presents Data on Systemic Delivery of NeuGene Antisense Drug to Treat Cardiovascular Restenosis
23 days October 25, 2005, Portland, Oregon Results From AVI BioPharma’s Antiviral Program Published in Two Virology Journals
23 days October 6, 2004, Portland, Oregon Written Testimony of Alan P. Timmins: BioShield II: Responding to An Ever-Changing Threat
23 days June 1, 2004, Portland, Oregon AVI BioPharma’s NeuGene Antisense Shows Inhibition of Dengue Virus
23 days October 1, 2002, Portland, Oregon Avi Announces Positive Interim Results of Phase II Antisense Trial For Cardiovascular Restenosis
26 days February 9, 2006, Portland, Oregon Successful Muscular Dystrophy Treatment Results Using AVI BioPharma Technology Published in Nature Medicine
26 days September 10, 2004, Portland, Oregon AVI BioPharma Presents Antisense Approach to Transplant Acceptance By Regulating Activated Lymphocytes
28 days December 21, 2004, Portland, Oregon AVI BioPharma Announces NeuGene Antisense Collaboration With the Walter Reed Army Institute of Research
28 days November 10, 2004, Portland, Oregon AVI BioPharma Reports Final Results From Resten-NG AVAIL Clinical Trial and Updates Its Cardiovascular Restenosis Program
29 days April 5, 2004, Portland, Oregon AVI BioPharma Expands Management Team
30 days May 21, 2002, Portland, Oregon Avi BioPharma to Present Avicine Pancreatic Cancer Survival Data At American Society of Clinical Oncology
35 days December 18, 2002, Portland, Oregon Avi BioPharma and International Therapeutics Enter Research Agreement to Target HIV Virus
36 days May 14, 2003, Portland, Oregon Avi Files for Orphan Designation for its West Nile Virus Drug
42 days January 25, 2005, Portland, Oregon AVI BioPharma Updates Progress on Infectious Disease Program Using NeuGene Antisense Drugs For RNA Viruses
47 days April 20, 2005, Portland, Oregon AVI BioPharma Presents Positive Results With NeuGene Antisense Drugs At the American Association for Cancer Research Meeting
48 days November 17, 2005, Portland, Oregon AVI BioPharma Strengthens Scientific Advisory Board to Address Infectious Disease and Avian Influenza
52 days January 26, 2004, Portland, Oregon AVI BioPharma Reports Successful NeuGene Antisense Approach To Regulation of the Immune Response in Transplantation
56 days July 26, 2005, Portland, Oregon AVI BioPharma Reports Continued Success in Preclinical Antiviral Efforts
61 days August 1, 2002, Portland, Oregon Avi BioPharma Completes NeuGene Antisense Clinical Trial In Patients With Polycystic Kidney Disease

CALENDAR ORDER
waiting days June 5, 2006, Portland, Oregon AVI BioPharma Presents Preclinical Results Preventing and Treating Diabetes Using Its ESPRIT Exon Skipping Technology
12 days May 24, 2006, Portland, Oregon AVI BioPharma Receives Notice of Allowance for a Patent Application Covering the Use of NeuGene Antisense Technology for the Development of a New Class of Antibiotics
14 days May 10, 2006, Portland, Oregon AVI BioPharma Presents Initial Results on Hepatitis C Virus Clinical Trial at the International Conference on Antiviral Research Annual Meeting
1 days May 9, 2006, Portland, Oregon AVI BioPharma Reports Preclinical Data Against Multiple Strains of Influenza
19 days April 20, 2006, Portland, Oregon AVI BioPharma Provides Update on Hepatitis C Virus Clinical Trial Status
21 days March 30, 2006, Portland, Oregon AVI BioPharma Reports Successful Inhibition of Multiple Subtypes of Influenza A Using NeuGene Antisense Therapeutic
17 days March 13, 2006, Portland, Oregon AVI BioPharma and Cook Group Enter Into License Agreement to Develop NeuGene Drugs for Vascular Diseases
6 days March 7, 2006, Portland, Oregon AVI BioPharma Successful Ebola Study Results Highlighted in Nature Reviews Drug Discovery
26 days February 9, 2006, Portland, Oregon Successful Muscular Dystrophy Treatment Results Using AVI BioPharma Technology Published in Nature Medicine
13 days January 27, 2006, Portland, Oregon AVI BioPharma Announces Hepatitis C Virus License Agreement With Chiron
7 days January 20, 2006, Portland, Oregon AVI BioPharma Reports Confirmation of Efficacy Against Influenza Strains
7 days January 13, 2006, Portland, Oregon AVI BioPharma’s NeuGene Shows Success Against Deadly Ebola Virus
3 days January 10, 2006, Portland, Oregon AVI BioPharma Reports Favorable Safety and Pharmacokinetic Data From Its Clinical Trial Targeting Hepatitis C Virus
6 days January 4, 2006, Portland, Oregon Increased Defense–Related Funding of AVI BioPharma Approved
48 days November 17, 2005, Portland, Oregon AVI BioPharma Strengthens Scientific Advisory Board to Address Infectious Disease and Avian Influenza
23 days October 25, 2005, Portland, Oregon Results From AVI BioPharma’s Antiviral Program Published in Two Virology Journals
4 days October 21, 2005, Portland, Oregon AVI BioPharma Provides Update on Influenza Drug Development Program
2 days October 19, 2005, Portland, Oregon AVI BioPharma Announces Presentation of Data at Transcatheter Cardiovascular Therapeutics Conference
5 days October 14, 2005, Portland, Oregon AVI BioPharma Updates Results From Department of Defense Funded Collaborative Programs
11 days October 3, 2005, Portland, Oregon AVI BioPharma Included in Initial Defense Funding Allocation
4 days September 29, 2005, Portland, Oregon AVI BioPharma Introduces ESPRIT With Initial Application in Muscular Dystrophy
1 days September 28, 2005, Portland, Oregon AVI BioPharma Initiates Hepatitis C Clinical Trial
8 days September 20, 2005, Portland, Oregon AVI BioPharma Initiates Phase II Cardiovascular Clinical Study in Europe
56 days July 26, 2005, Portland, Oregon AVI BioPharma Reports Continued Success in Preclinical Antiviral Efforts
7 days July 19, 2005, Portland, Oregon AVI BioPharma Announces Publication of SARS NeuGene Antisense Studies in the Journal of Virology
19 days June 30, 2005, Portland, Oregon AVI BioPharma Submits IND for NeuGene Antisense Drug Targeting Hepatitis C Virus
10 days June 20, 2005, Portland, Oregon AVI BioPharma and Collaborators Announce Positive Results With NeuGene Antisense Drugs at American Society for Virology Annual Meeting
0 days June 9, 2005, Portland, Oregon AVI BioPharma to Testify Before Congressional Committee on Bioterrorism Research and Development
11 days June 9, 2005, Portland, Oregon Crossing The Valley Of Death: Bringing Promising Medical Countermeasures To Bioshield Written Testimony of Alan P. Timmins President and Chief Operating Officer AVI Biopharma, In
3 days June 6, 2005, Portland, Oregon AVI BioPharma Announces Positive Results With Neugene Antisense Drugs at the Endocrine Society Annual Meeting
47 days April 20, 2005, Portland, Oregon AVI BioPharma Presents Positive Results With NeuGene Antisense Drugs At the American Association for Cancer Research Meeting
8 days April 12, 2005, Portland, Oregon AVI BioPharma Announces Positive Results in NeuGene® Antisense Studies With Collaborators Targeting Emerging Viral Diseases
13 days March 30, 2005, Portland, Oregon AVI BioPharma Announces Publication of West Nile and Dengue Virus NeuGene Antisense Studies in the Journal of Virology
22 days March 8, 2005, Portland, Oregon AVI BioPharma Announces New Board Member Appointments
42 days January 25, 2005, Portland, Oregon AVI BioPharma Updates Progress on Infectious Disease Program Using NeuGene Antisense Drugs For RNA Viruses
6 days January 19, 2005, Portland, Oregon AVI BioPharma Receives Key U.S. Patents Covering Preservation and Expansion of Stem Cells Using Third-Generation NeuGene Antisense
1 days January 18, 2005, Portland, Oregon AVI BioPharma Appoints Vice President of Cardiology
28 days December 21, 2004, Portland, Oregon AVI BioPharma Announces NeuGene Antisense Collaboration With the Walter Reed Army Institute of Research
13 days December 8, 2004, Portland, Oregon AVI BioPharma Updates Third-Generation NeuGene Antisense Program
28 days November 10, 2004, Portland, Oregon AVI BioPharma Reports Final Results From Resten-NG AVAIL Clinical Trial and Updates Its Cardiovascular Restenosis Program
9 days November 1, 2004, Portland, Oregon AVI BioPharma and USAMRIID Announce NeuGene Antisense Drug Demonstrates Efficacy Against Ebola Virus
3 days October 29, 2004, Portland, Oregon AVI BioPharma NeuGene Antisense Drugs Suppress Influenza A Virus
23 days October 6, 2004, Portland, Oregon Written Testimony of Alan P. Timmins: BioShield II: Responding to An Ever-Changing Threat
26 days September 10, 2004, Portland, Oregon AVI BioPharma Presents Antisense Approach to Transplant Acceptance By Regulating Activated Lymphocytes
10 days August 31, 2004, Portland, Oregon AVI BioPharma Announces Initiation of Acute West Nile Virus Clinical Study
8 days August 23, 2004, Portland, Oregon AVI BioPharma Announces Dengue Virus Collaboration With CDC
13 days August 10, 2004, Portland, Oregon AVI BioPharma Announces NeuGene Antisense Collaboration With USAMRIID on Biodefense Agents
20 days July 21, 2004, Portland, Oregon AVI BioPharma Receives Notice of Allowance for Key Patent Application Covering NeuGene Antisense Technology for RNA Viruses
21 days June 30, 2004, Portland, Oregon AVI BioPharma Announces Termination of Cardiovascular Agreement With Medtronic
6 days June 24, 2004, Portland, Oregon U.S. Senate Committee on Appropriations Directs $10 Million For Defense-Related Research to AVI BioPharma
23 days June 1, 2004, Portland, Oregon AVI BioPharma’s NeuGene Antisense Shows Inhibition of Dengue Virus
12 days May 20, 2004, Portland, Oregon Journal of Virology Publication Highlights Antiviral Activity Of AVI BioPharma’s NeuGene Antisense Compound
16 days May 4, 2004, Portland, Oregon AVI BioPharma Presents Additional Data on West Nile Virus Clinical Trial At International Antiviral Conference
29 days April 5, 2004, Portland, Oregon AVI BioPharma Expands Management Team
4 days April 1, 2004, Portland, Oregon AVI BioPharma Reports Anti-Cancer Effects and Single-Dose Bioavailability With NeuGene Antisense Compounds
10 days March 22, 2004, Portland, Oregon AVI BioPharma Announces Additions to Board of Directors
4 days March 18, 2004, Portland, Oregon AVI Reports Positive Clinical Results On Oral Delivery of Its NeuGene Antisense Drug
52 days January 26, 2004, Portland, Oregon AVI BioPharma Reports Successful NeuGene Antisense Approach To Regulation of the Immune Response in Transplantation
17 days January 9, 2004, Portland, Oregon AVI BioPharma Reports Inhibition of SARS Coronavirus With NeuGene Antisense Drugs
1 days January 8, 2004, Portland, Oregon AVI BioPharma Bolsters Clinical and Regulatory Expertise
9 days December 30, 2003, Portland, Oregon AVI BioPharma Announces Results From West Nile Virus Clinical Trial
7 days December 23, 2003, Portland, Oregon AVI BioPharma Reports Confirmation of Positive Phase II Clinical Results In Restenosis
13 days December 10, 2003, Portland, Oregon AVI Presents Preclinical Data on Microbubble Drug Delivery And NeuGene Antisense Anti-Cancer Strategies
6 days December 4, 2003, Portland, Oregon AVI BioPharma Antisense Drug Successfully Treats Feline Viral Outbreak
17 days November 17, 2003, Portland, Oregon AVI BioPharma Announces Publication of Prostate Cancer Results
4 days November 13, 2003, Portland, Oregon AVI BioPharma Announces Presentation of Data And Filing for Orphan Designation in Polycystic Kidney Disease
2 days November 11, 2003, Portland, Oregon AVI BioPharma Presents Antisense Antiviral Technology at SMi Conference
5 days November 6, 2003, Portland, Oregon AVI Presents Data on Microbubble Delivery of Restenosis Drug At American Heart Association Annual Meeting
1 days November 5, 2003, Portland, Oregon AVI BioPharma Presents Preclinical Data on Cholesterol-Lowering Program
7 days October 29, 2003, Portland, Oregon AVI BioPharma Updates Progress on Infectious Disease Program Using NeuGene Antisense For RNA Viruses
19 days October 10, 2003, Portland, Oregon AVI Initiates Clinical Study to Evaluate the Oral Efficacy of Its NeuGene Antisense Drug
2 days October 8, 2003, Portland, Oregon AVI BioPharma to Initiate Second West Nile Virus Clinical Study With NeuGene Antisense Drug
20 days September 18, 2003, Portland, Oregon AVI BioPharma Reports Positive Phase II Clinical Results in Restenosis
8 days September 10, 2003, Portland, Oregon AVI BioPharma Begins Clinical Trial of West Nile Virus Patients
6 days September 4, 2003, Portland, Oregon AVI Reports Positive Independent Results With NeuGene Antisense Compound Targeting SARS
2 days September 2, 2003, Portland, Oregon AVI BioPharma Announces Termination of Merger Agreement, Exchange Offer With eXegenics, Inc.
14 days August 19, 2003, Portland, Oregon Avi Begins Phase II Study of Systemic Delivery Of Resten-NG in Restenosis
5 days August 14, 2003, Portland, Oregon Avi Files for Orphan Designation for Its SARS Coronavirus Antisense Drug
3 days August 11, 2003, Portland, Oregon Avi BioPharma Announces Increase in Exchange Ratios For eXegenics Capital Stock and Extends Expiration Date to Aug. 29, 2003
7 days August 4, 2003, Portland, Oregon Avi BioPharma Is Cleared to Initiate Clinical Trial for West Nile Virus With NeuGene Antisense Drug
5 days July 30, 2003, Portland, Oregon Avi BioPharma Updates Progress on Cardiovascular Disease Program With NeuGene Antisense
1 days July 29, 2003, Portland, Oregon and Dallas, Texas Avi BioPharma and eXegenics Announce Commencement of Exchange Offer For eXegenics Common Stock and eXegenics Preferred Stock
7 days July 22, 2003, Portland, Oregon Avi BioPharma Publishes Prostate Cancer Results
6 days July 16, 2003, Portland, Oregon and Dallas, Texas Avi BioPharma to Acquire eXegenics in $11.0 Million Stock Exchange
1 days July 15, 2003, Portland, Oregon Avi BioPharma Presents Positive Results With its Novel Antisense Drug For Prostate Cancer
6 days July 9, 2003, Portland, Oregon Avi BioPharma CEO to Present at International Science Symposium On SARS in China
2 days July 7, 2003, Portland, Oregon Avi BioPharma Manufactures West Nile Virus Antisense Drug
6 days July 1, 2003, Portland, Oregon Avi BioPharma Added to Russell 3000 Index
1 days June 30, 2003, Portland, Oregon Avi BioPharma Files IND With FDA For West Nile Virus NeuGene Antisense Drug
7 days June 23, 2003, Portland, Oregon Gerald Zon Joins AVI BioPharma Scientific Advisory Board
3 days June 20, 2003, Portland, Oregon Avi BioPharma Announces Positive Data on New Prostate Cancer Target
1 days June 19, 2003, Portland, Oregon Avi BioPharma Reports Positive Results From NeuGene Cancer Trial
36 days May 14, 2003, Portland, Oregon Avi Files for Orphan Designation for its West Nile Virus Drug
7 days May 7, 2003, Washington D.C. Dr. Denis Burger's Written Testimony from House Energy and Commerce SARS Hearing
1 days May 6, 2003, Portland, Oregon Avi BioPharma to Testify at House Energy and Commerce SARS Hearing
7 days April 29, 2003, Portland, Oregon Avi BioPharma Announces Presentation on Antiviral Antisense Program
1 days April 28, 2003, Portland, Oregon Avi BioPharma Announces Preclinical Testing Plan For SARS Antisense Compound
4 days April 24, 2003, Portland, Oregon Avi BioPharma Completes West Nile Virus Preclinical Development Program
22 days April 2, 2003, Portland, Oregon Avi BioPharma Presents Data on Systemic Delivery of NeuGene Antisense Drug to Treat Cardiovascular Restenosis
7 days March 26, 2003, Portland, Oregon Avi BioPharma Advances NeuGene Antisense Cancer Program
6 days March 20, 2003, Portland, Oregon Avi BioPharma Updates Progress in Single Stranded RNA Viruses With NeuGene Antisense Compounds
1 days March 19, 2003, Portland, Oregon Avi BioPharma Reports Update of NeuGene Antisense Clinical Development Program for 2002, Plans for 2003
6 days March 13, 2003, Portland, Oregon Avi BioPharma Scientist Presents Data Showing Novel Antisense Inhibits Gene Expression of Metabolic Enzyme in Human Liver
15 days February 26, 2003, Portland, Oregon Avi Announces Final Results of NeuGene Antisense Study In Polycystic Kidney Disease Patients
6 days February 20, 2003, Portland, Oregon Avi BioPharma Study Results Reveal Increased Utility for NeuGene Antisense Drug
0 days January 31, 2003, Portland, Oregon Avi Awarded Grant From National Cancer Institute to Target Prostate Cancer with NeuGene Antisense Drugs
20 days January 31, 2003, Portland, Oregon Avi NeuGene Antisense Drug Increases Effectiveness Of Chemotherapy in Treating Lung Cancer
9 days January 22, 2003, Portland, Oregon Avi Presents Data on Oral Delivery of NeuGene Antisense Drugs at Prestigious Scientific Symposium
35 days December 18, 2002, Portland, Oregon Avi BioPharma and International Therapeutics Enter Research Agreement to Target HIV Virus
0 days December 12, 2002, Portland, Oregon Avi BioPharma Completes Clinical Trials With NeuGene Antisense Targeting Drug Metabolism
6 days December 12, 2002, Portland, Oregon Avi Presents NeuGene Antisense Data Targeting Prostate Cancer At Scientific Conference
7 days December 5, 2002, Portland, Oregon Avi Announces Promising NeuGene Antisense Results Targeting Viruses
15 days November 20, 2002, Portland, Oregon Clinical Trial Supports Further Study of AVI's NeuGene Antisense In Polycystic Kidney Disease Patients
1 days November 19, 2002, Portland, Oregon Studies Support Targeted Systemic Delivery of NeuGene Antisense To Treat Coronary Arteries
14 days November 5, 2002, Portland, Oregon Avi BioPharma Initiates New Round of Human Clinical Trials With NeuGene Antisense Targeting Drug Metabolism
6 days October 30, 2002, Portland, Oregon Avi's Combination Antisense Strategy Inhibits Tumor Growth In Human Prostate Cancer Models
1 days October 29, 2002, Portland, Oregon Study Supports Topical Application of AVI's NeuGene Antisense
5 days October 24, 2002, Portland, Oregon Avi BioPharma Confirms Availability of Additional Route Of Administration for NeuGene Antisense Drugs
23 days October 1, 2002, Portland, Oregon Avi Announces Positive Interim Results of Phase II Antisense Trial For Cardiovascular Restenosis
61 days August 1, 2002, Portland, Oregon Avi BioPharma Completes NeuGene Antisense Clinical Trial In Patients With Polycystic Kidney Disease
8 days July 24, 2002, Portland, Oregon Promising Results of AVI BioPharma Colorectal Study Featured In Clinical Cancer Research
13 days July 11, 2002, Portland, Oregon Avi BioPharma Demonstrates Effective Delivery of NeuGene Antisense Therapeutics
16 days June 25, 2002, Portland, Oregon Avi BioPharma NeuGene Antisense Study Featured In Drug Metabolism and Disposition
5 days June 20, 2002, Portland, Oregon Avi BioPharma Presents Effectiveness of NeuGene Antisense Agent In Inhibiting Prostate Cancer Cell Growth
30 days May 21, 2002, Portland, Oregon Avi BioPharma to Present Avicine Pancreatic Cancer Survival Data At American Society of Clinical Oncology
1 days May 20, 2002, Portland, Oregon Avi BioPharma Demonstrates Effectiveness of NeuGene Antisense Agents As Potential Antibiotics Targeting Calicivirus and E. Coli
3 days May 17, 2002, Portland, Oregon Avi BioPharma to Present Novel Antisense Approach at Leading Interventional Cardiology Conference
2 days May 15, 2002, Portland, Oregon Avi BioPharma Appoints Andrew J. Ferrara to Board Of Directors
1 days May 14, 2002, Portland, Oregon Avi BioPharma Scientists Publish Results of Antisense Drug In Treating Cancer and Viral Infections
4 days May 10, 2002, Portland, Oregon Avi BioPharma Demonstrates Effectiveness of Antisense Drug In Treating Symptoms of Polycystic Kidney Disease
3 days May 7, 2002, Portland, Oregon Avi BioPharma Announces Clinical Study Results Providing the First Definitive Evidence of Antisense Efficacy in Humans
5 days May 2, 2002, Portland, Oregon Avi BioPharma Announces Plans to Initiate Phase III Clinical Trial In Pancreatic Cancer With Avicine
3 days April 29, 2002, Portland, Oregon Avi BioPharma Initiates Clinical Development Program For NeuGene Antisense Treatment of Coronary Artery Bypass Grafts
6 days April 23, 2002, Portland, Oregon Avi BioPharma Scientist Presents Data Showing Novel Antisense Inhibits Gene Expression of Metabolic Enzyme in Human Liver
14 days April 9, 2002, Portland, Oregon Avi BioPharma Scientist Presents Novel Antisense Approach For Prostate Cancer at AACR 93rd Annual Meeting
19 days March 21, 2002, Portland, Oregon Avi BioPharma Announces Efficacy of Oral Administration Of Its Proprietary NeuGene Antisense Agents in Rats
17 days March 4, 2002, Portland, Oregon Avi BioPharma Scientists to Present Novel Antisense Approach For Prostate Cancer and Emerging Infectious Diseases at Conferences Worldwide
20 days February 12, 2002, Portland, Oregon Avi BioPharma Obtains Worldwide Exclusive Rights To Important Viral Target
7 days February 5, 2002, Portland, Oregon Avi BioPharma Opens GMP Manufacturing Plant For NeuGene Antisense Drugs for Clinical Trials and Commercialization

Private - A Scary Thought & Game Changers

2005-12-06T08:38:00.000-08:00

As of 9/30/05, Invus Public Equities Advisors, L.L.C., 135 East 57th Street, 30th Floor, New York, New York had acquired 700,000 shares, $1,484,000 worth of AVI Biopharma shares per their 13 F Filing.

It's nice to see some more institutional interest or is it?

Raymond Debbane is the President of Invus and is on the board of Ceres.
Mr. Debbane is the President and Chief Executive Officer of The Invus Group, Ltd., a New York-based private equity investment firm which is the exclusive investment advisor of Artal Luxembourg S.A., a shareholder of Ceres. Mr. Debbane was a director of Plant Genetic Systems N.V. representing Artal, a founder and major investor of that company. Mr. Debbane has served as a director of Ceres since March 1998.

Artal Luxembourg S.A. has an exclusive investment advisor: Invus Public Equities Advisors, L.L.C.

Artal is a European-based private equity company with several billion dollars in capital under management. Artal was the lead investor in the first-generation plant biotechnology company, Plant Genetic Systems that was sold to Hoechst Schering AgrEvo GmbH in 1996. Artal's exclusive investment advisor, The Invus Group has over its seventeen-year history led leveraged buy-out (LBO) and venture capital investments in over 50 portfolio companies in a wide range of industries including food, specialty retailing, software, telecommunications, medical devices and biotechnology. These investments include the 1999 LBO of Weight Watchers International from the H.J. Heinz Company followed by the Weight Watchers IPO in November of 2001 and the 1996 LBO acquisition and turnaround of the Keebler Foods Company followed by a 1998 IPO.

Recall, we are in AVI Biopharma because it has the potential to become the medical game changer! - Cardiovascular Restenosis - Single strand viruses: Flu, Avian Flu, Hepatitis-C, Common Cold, Sars, Denegue, Rift Valley, Denegue, West Nile, Ebola, Marburg - Antitoxins: Ricin, Anthrax - Gene Therapy: Duchenne Muscular Dystrophy and that is probably just the start, MS and Diabetes are possibilities - Cancer - Neubiotics: E-Coli.

What is a company worth that can address all these medical needs? It is hard to believe that AVI Biopharma will not be in the club of drug manufacturers and biotechs with market caps over $1 Billion. There are only 65 or so members today. Or possibly joining the 25 members of the $10B plus market cap club.

Isn't AVI Biopharma a game changer?

The thought that AVI could go private is disturbing, though obviously there will be a premium, if it happens and the short term returns may be higher.

If MSFT had gone private in 1992, investors in the stock would have lost the chance to make 12.5x return over the next 13 years! MSFT was the game changer of the 90's in software. Will AVII be the game changer in pharma?

************************************************************************************
DOD Presentation from April with AVI's SAR'S slide. Also note on page 5 Dr. Klaus Shafer, who is now on AVI's Scientific Advisory Board.

Morpholino Superior to ISIS antisense for DMD

See disclosure below. Do your own due diligence. This is not trading or investment advice.

AVI Biopharma (AVII) an update. Much is happening.

2005-11-28T15:28:00.000-08:00

From mercado_ron on a message board:

"Here are all the things that can happen between now and about mid January that could signficantly move the stock: 1) There seems to be no doubt at this point that the Phase I part of the HCV trial is complete and that the second Phase with 40 patients will start sometime in the next two weeks. Based on this likely accurate assumption, initial data (3 day, 7 day, 14 day) will be coming out of the trial as test results come back from the lab. As Nerd has pointed out, this is an Open Label trial, so it is likely that these results will be known beyond the confines of the company. We may not get an official press release on these results until sometime in the first quarter or even Q2 if they wait for the follow up period to end. But there is little doubt that investors and potential partners will know these results within the next 6 weeks. This is similar to the Ebola data, which still hasn't made its way officially into the public domain until we get publication. Based on the strong preclinical data, which is briefly highlighted on Clinicaltrials.gov, the data from Scripps and the trial design approved by the FDA, it seems AVI is positioned to go from practically unknown in the HCV world to the leading drug candidate, almost out of nowhere (none of the major analysts are following this trial). HCV data, even unconfirmed, could take this stock into the $6 to $8 range and much higher upon confirmation. 2) ESPRIT - Its only a matter of time for AVI to announce its collaboration with Glaxo on a MD human trial. This is not a big money deal, but it would be technology validation. While the timeframe is unclear, AVI is definately working on partnering this same aspect of their technology toward Diabetes. Obviously, this is a big market and one would think that Glaxo would recognize that if they have had a front row seat to the MD results from Wilton. Expect something to happen here in 2006, but that we may get a preview in the next few months. 3) Ebola data publication - Yes, I know, this has been talked about for almost a year! It will happen. In fact, there is a good shot of it coming out in December. While we are all fatigued from talking about it, the specific results, implications and peer reviewed analysis will provide a huge credibility boost and generate more media for the company. It will also boost AVI's efforts to secure funding for its goverment projects, most notably H5N1. 4) Avian Flu - The company is setting up animal testing for its H5N1 drug after initial data has proven its effectivness across most Influenza A subtypes. The company is definately making a significant investment in this area as H5N1 is no SARS. It is a true crisis in the making and there is no doubt that our goverment and world governments are going to throw TONS of money at this virus once it elevates to the next level. Events unfoling in Indonesia, China, Vietnam and now the Middleast are setting off signficant danger signals and we are getting closer to the WHO raising its pandemic warning level to 4 from 3. That will put the world on crisis footing. It should be noted that because of AVI's rapid development timeline, the PMO's incredible safety profile and the proposed legislation (allow for use of experimental drugs in crisis), AVI's H5N1 antiviral can actually be in production and use in 2006 (production being the biggest issue). Since none of the existing antiviral has proven they will do more than be marginally effective, a new proven antiviral would be backed with signficant resources. It would be almost a given that one of the companies the most to lose from a "Tamiflu" or "Relenza" replacement would seek to partner with AVI at an early stage, sucking up grant money and insuring that as future orders for Tamiflu and Relenza start to get canceled (deliveries are now backed up into 2008), they will see new stockpiling orders for the AVI antiviral. Possible partners, Roche, Glaxo, Gilead, etc. 5) Resten MP - Rumors out there that initial results look good. Follow up period is fairly long, so we won't likely be seeing data until well into Q2 or later. However, once again, trial info will seep out. Resten MP's effectivness turns the drug eluting stent market on its head. AVI's partner on this drug would cause havoc in the US market. The European market would be a given, but the US market where $2,000 plus drug eluting stents are now the standard of care, might undergo some serious pain. Of course, AVI is still looking to launch their Resten NG trial, which may get annoucned in the next 6 weeks. That would be a positive for the stock, but if Resten MP works well, why bother? Either way, AVI wins and wins big. 6) Neubiotics - Nobody wants to invest money to make an antibiotic that is then rationed and used sparingly so resistence doesn't develop. Yet, there is a huge growing need for new antibiotics that is not being met by big pharma. Enter AVI's 5 year old program that has taken on a new life thanks to the PPMO. Check out the IC-50 values in that latest published paper!!! Imagine what these PPMO's can due to e-coli and other bacteria! Well, AVI isn't imagining, they are testing. Look for this program to emerge in 2006 with a major partner. 7) Dengue - AVI is likely to move into a human trial on Dengue in 2006, but with government funding support and collaboration. This virus is a major problem in large parts of the world. While the commercial opportunity may be somewhat limited, foreign governments, foundations and world health organizations will together create a large and lucrative market for this drug, which will largely be funded by grants and the development costs buffered via government collaboration. Just another application extension of the ssRNA opportunity. And of course, there is more, from the preclinical work on Cancer to the company's stem cell opportunity. Not that its a great analogy, but having this technology at your disposal during a time period that new genetic targets are being discovered and seequnced each month must be hard to deal with. Think of the kids walking into Willy Wonka's factory and being let loose! So many opportunties to impact everything from arthritis and obesity to killer diseases or all sorts. From a lab perspective, it must be like being a kid in a candy store or a one eyed dog in a butcher shop. So long as the clinical trial focus remains on track, this early stage research work, which is largely being done with outside collaborators (mostly with top notch institutions), is setting the stage for future opportunties. Once AVI's technology is validated in one or two areas, it will become self evident that these other applications can will be successfully developed. Antisense will go from a discredited area of biotech into the hottest area in medicine, but there will be only ONE company that has the keys to the kingdom. What will that company and technology be worth once this realization happens? How could it possibly be valued? Let's just say that it will be EXTREMELY painful to watch all of these warrants get excercised for chump change. But, in fairness, the market will be so large and the opportunties so bountiful, that it won't much matter if there are 50 million or 100 million shares out. People in at the sub $10 level will still make a ton of money. Well, that's if the company doesn't get bought in the next 12 to 18 months. It should be an interesting 6 weeks. Let's see how it plays out."*********************************************************************

Unfortunately with AVI Biopharma could happen and will happen are often two very distinct universes! My money is on some of it happening though.

*********************************************************************
If this clinical trial, Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy, sponsored by the Imperial College London uses AVI Biopharma's PMO or PPMO chemistry, this may be viewed as a major endorsement of the science. Recall earlier I cited a presentation by Glaxo showing they were supplying the drugs for this and they would be based on AVI's science.

********************************************************************

From comments:
frog said...

"You may wish to consider that the Restin MP EU trial design, data gathering and evaluation is being conducted by Harvard. A very independent and professional outfit. Which is very important if the data is to be part of any future FDA IND.

The issue of what are the clinical trial goals at AVII and how do they measure them has always been fairly obvious..AVII has always stated that they seek partnership for late stage clinical trials.

Furthermore, AVII has wisely not gotten caught up in the rush to ph-3 clinical regardless of the merit (sans isis, gnta, etc. Consequently they have no failed clinical trials.

By keeping their eye on the goal of refining their science and thus the scope of applications, they are now in a great position to leverage this science into solid reality. Their science is in the best possible position to benefit from genetic research and the almost daily discoveries of new DNA based code"

11:20 AM

***********************************************************************

AVI BioPharma Strengthens Scientific Advisory Board to Address Infectious Disease and Avian Influenza

Klaus O. Schafer, M.D., MPH, is the former deputy assistant to the Secretary of Defense for Chemical and Biological Defense. In this position, Dr. Schafer oversaw the $2.1 billion annual science, technology, research, development and acquisition program in the area of medical and nonmedical materials for chemical biological defense for the entire U.S. Department of Defense.

David N. Gilbert, M.D., MACP, is a professor of medicine at Oregon Health & Science University and former president of the Infectious Diseases Society of America.

Thomas G. Voss, Ph.D., is currently an assistant professor in the department of microbiology and immunology at Tulane University School of Medicine. His current research involves developing animal models for testing vaccines, diagnostics and therapeutics against biodefense and emerging infectious diseases, including avian influenza. His previous research involves developing novel approaches for the treatment of anthrax, screening antiviral drugs against SARS coronavirus, and developing in vitro and animal models for testing the efficacy of innate immunity activators for prevention of infection and disease by viral, bacterial and other infectious agents.

Seems to me that AVI Biopharma has made some worthwhile additions to their advisory board!

***************************************************************

It is encouraging to see an AVI director buy a small amount of stock on the open market! Way to go, Jim!

It would be very encouraging, if AVI were to bring in an outside Chairman of the Board that was not a member of the old boys club. Some true independent thinking would be welcome!

Time will tell what will happen. Hopefully we see the stock price reflect the real value of the science!

Speaking of time, Micro is and expects to be busy so updates will be more sporadic than I like.

Micro

see disclaimer below

AVII and Restenosis Trial

2005-11-18T21:50:00.000-08:00

From a poster, who knows 10x more about the science than I ever will, on the Yahoo boards ...Restenosis Comment "German clinical trial going extremely well. 20+ patients enrolled and initial clinical observations...no restenosis!!!"

If the information he has been given is correct, this is big!

From the clinical trial write-up: "Primary Outcomes: Evaluate the potential efficacy of RESTEN-MP given intravenously upon confirmation of stent implantation and again at 24 hours post stent implantation.; The therapeutic endpoint to assess potential efficacy is the prevention of coronary late lumen loss 6 months after the stent placement procedure, based on Quantitative Coronary Angiography (QCA).
Secondary Outcomes: •Major Cardiac Adverse Events (MACE) defined as cardiac death, MI (Q wave and non-Q wave), emergent cardiac bypass surgery, and clinically-driven target lesion revascularization (TLR) at Days 14 and 30, and Month 6, 9 and 12 post-stent placement.; •Target Vessel Failure (TVF) rate, defined as a composite of target vessel revascularization, recurrent MI (Q or Non Q-Wave), or cardiac death that could not be clearly attributed to a vessel other than the target vessel at Month 9 post-stent placement.; •Angiographic binary restenosis (≥ 50% diameter stenosis) at Month 6 post-stent placement.; •In-stent minimum lumen diameter (MLD) at Month 6 post-stent placement.; •In-segment MLD at Month 6 post-stent placement.; •Proximal and distal late loss at Month 6 post-stent placement.; •In-stent and in-segment percent (%) diameter stenosis at Month 6 post-stent placement.
Expected Total Enrollment: 50"

I am gathering that what was reported was based on 14 day and maybe some 30 day data. The 6 month data is when this really gets interesting! But, there is such a large data base on stents and their effects, the early data may be very indicative.

Micro

see disclaimer below

Dutton rates AVII a Speculative Buy + Comments

2005-11-16T20:41:00.000-08:00

Dutton rates AVII a Speculative Buy with a $5.00 price target.

A very detailed report, sure hope that $5.00 price target is wildly conservative.

******************************************************

Ronald said...

The Barrons piece was very good and timing excellent as it kept the price (so far) at the offering price. So often when a company announces a private placement of any type the stock drops but in this case there had been a run up on no news so the drop in effect had meaning as it just brought the price back to where it was.

3:08 AM

Anonymous said...

Your viewpoints of Avi are thoughtful and for the most part on target... Thanks for the insight.

I think Avi would serve itself well if it were to instigate a benchmarking study of their clinical trials. And then set performance measures to ensure that their clinicals are indeed competitive and that the clinicals have clear focus that meets the mission of AVI the Organization.

Robben...

Hello,

your summary is really a very good work. Please enable, that this great work will be found by appropriate search entries on search machines (Google)

Thanks for your effort

Uli

9:35 AM

******************************************************************************

Thank you for your kind comments.

I spent many years at a Fortune 500 company and agree benchmarking is a critical element. When I read of 11 completed clinical trials and then realize there is nothing beyond Phase II, I wonder about the focus. Setting of performance to assure meeting goals is very important.

Key questions:
1) Are they really targeting the goal line?
2) Have they identified the goal line?
3) Are the actions they are taking consistent with reaching the goal line?

If others have different ideas, additional key questions, or comments on these please let me know. Either leave a comment below and/or send me an email at themicrokid at yahoo.com

Have a great day and IT’S NOT ABOUT THE PRICE TODAY,
IT’S ABOUT THE PRICE IN THE FUTURE!

Micro

see disclaimer below

Comment on Micro's Blog & AVII

2005-11-15T08:18:00.000-08:00

Anonymous said...

"Micro,

I have been saying your blog was objective on AVII. It seems you gave a despicable managment team a pretty light pass."

8:14 AM

Anonymous, I called AVI's management a few names in my office yesterday before I calmed down enough to collect all my thoughts. Your use of "despicable" seems a mite strong in my thinking. But, I am not in their shoes, so I don't know the pressures on them and the difficulties they have in making a deal that benefits stockholders.

I suspect the difficulties in making a deal are far greater than AVI's management thought they would be, even with the trials running today. If you look back at the history of AVI’s deals, in hindsight they look pretty poor – Supergen, Medtronic…... It is of course easy to look back in hindsight!

We are talking today about curing avian flu, but people are forgetting the dollars to be made in curing the regular flu!

Every year 5% to 20% of the US population gets the flu! More than 200,000 people are hospitalized and about 36,000 die. A cure for the ordinary flu treating just 2% of the US population would be 6 million treatments per year. What revenue would 6 million treatments provide?

I am really in no hurry for them to make a deal. Negotiating 101: "A deal from a position of strength is much more attractive than a deal made in weakness!"

When I see people like George Haywood among the major shareholders of AVI, it gives me confidence. They may not listen well to the small stockholder, but I bet they listen when George talks.

I seriously doubt they broke the law as some have charged. I really think congress and the SEC needs to tighten up the law to protect investors.

I would hope that AVII would issue a press release stating some of the reasons for the PIPE.

No, I don’t think I gave Dr. Burger and his team a pass. Rather I stepped back and took a very pragmatic and long term view. I often choose stocks with the idea that I will be buying a potential homerun stock. I don’t get homeruns without staying invested. I have at least 8 triples in the past 4 years. None of them happened quickly and most happened by buying hated stocks.

Back to the topic at hand.

It would be great, if at the same time they gave shareholders some updates on key programs!

FIM Resten MP trial in Europe – How many patients have been treated? Is there anything else that can be reported? Considering that the press release for the Washington meeting said “preliminary findings,” I suspect Dr. Erbel said something in the poster session.

Rumor has it the HCV trial has completed the safety/dosing study and the Phase II will begin as soon as the FDA signs off on the data. Why not let the owners of the company know?

Did AVII fail to enroll in WNV patients this year? Again why don’t the shareholders have a right to know?

There seems to be a tendency in small companies to sweep failures under the rug. Then companies wonder why investors don’t trust them. Seems honest regular straightforward communications would go a long way in building shareholder trust.

There is little difference in my mind between technical program transparency and financial transparency that has destroyed so many companies.

I will repeat myself:

It’s the science and the longer the big guys don’t own the science, the more costly it will be for them to acquire the science. The cost to them will benefit the shareholders of AVII!

IT’S NOT ABOUT THE PRICE TODAY,
IT’S ABOUT THE PRICE IN THE FUTURE.

NeuGene®, ESPRIT™, Resten–MP™, and Resten–NG™ are trademarks of AVI Biopharma

I currently am long AVII stock. I also often swing trade a portion of my holdings.

I find it worthwhile to visit two message boards to learn more about AVI: http://finance.yahoo.com/q/mb?s=AVII There is a lot of noise here, but also some worthwhile info. http://groups.yahoo.com/group/thenewmorpholino/ This is a moderated message board, which must be joined, but has much more detail.

This blog is not meant to replace any resource on AVI.

This site has no relationship to AVI Biopharma.

Official AVI website: http://www.avibio.com and http://www.antivirals.com

It is solely my understanding. I bear no responsibility for the correctness or your use of the material contained within this site.
As always do your own due diligence and make your own decisions. No one knows for certain what tomorrow will bring. Only you can be responsible for your own decisions. I may hold bullish and/or bearish positions without warning and these may change without warning.

AVII .... ouch we tripped on a PIPE...but .....

2005-11-14T22:46:00.000-08:00

I still believe AVI Biopharma’s science will prevail!

I am disappointed they chose the low road of using a PIPE to get more funding. I would have much preferred a legitimate secondary. Maybe they discussed this with the investment bankers and concluded they couldn’t do one now?

It would sure seem they could have after positive results on the Hep C trial or the Resten MP trial from Europe.

The PIPE approach is probably a lot less costly to AVII, but it tends to hurt the shareholders. It does nothing to raise confidence in management! The good news is the management of AVII has kept the company alive while the technology developed and kept it independent. At least they did not deny they might seek additional financing when asked about it.

This PIPE means each share will have about 13.5% less of the company than they would have otherwise. If what I think happens does happen from successful trials in the next few months that 13.5% won’t matter a bit!

Plus the additional $22 million in the war chest will put AVII in a better bargaining position if there is an agreement of one or more of the drugs. It also may put AVII in a position to move one or more drugs along without a partnership. If that should happen, you may end up gaining much more than the 13.5% dilution that has occurred. Or it may allow one or more drugs to get to the finish line faster. Otherwise, the money may be used to help get a return on your money quicker. Or there is always the possibility the money may be wasted. I hope this is not the case.

What happens to the stock price now? I have no idea! The limited information we have on the PIPE was that it was at Friday’s close, $3.26. Did the institutions dump those shares on the back of the Barron’s article for a quick profit? As the SEC forms unfold, we should get some idea of this. Were there any warrants, as a part of this? Again time will tell.

What did I do? I sold some stock during the day and also bought some. I also sold some in after hours trading. As after hours drew to a close I jumped to the other side of the fence and started buying. I have fewer shares than I started with, but still have about 2/3 of the position I had Friday. If the stock drops from here, I will be buying at some point. If it goes up, I will also be buying at some point.

The idea documented in the Barron’s article that GSK is evaluating this technology is outstanding! The other $22 million the Senate is working on approving is great! The open trial on the HCV is very significant!

It’s the science and the longer the big guys don’t own the science, the more costly it will be for them to acquire the science. The cost to them will benefit the shareholders of AVII!

IT’S NOT ABOUT THE PRICE TODAY,
IT’S ABOUT THE PRICE IN THE FUTURE.

AVI Biopharma (NASDAQ: AVII) an update

2005-11-12T20:17:00.000-08:00

Fixed the patent link problem, Also added link to some patent applications. Replaced roadblog with roadblock. Added link to the video of Dr Burger on CNBC. Leave a comment or email me at themicrokid at yahoo.com. I will try to respond. If you want a paragraph rewritten, rewrite it and send it. If it makes sense to me I will use your rewrite. Just a quick update.

The Barron's article on AVII This is a very good overview of AVI Biopharma.\

Summary of Barrons article on message board, Part 1.

Summary of Barrons article on message board, Part 2.

Griffin Securities on Avian Flu with an AVII mention

The four AVI Clinical Trials

I have fixed these, test them, and then on a second test they failed again! I am now trying a different methodology. A bit baffled on these links!

Some of the issued patents in AVI's portfolio

Some Patrick Iversen patents

Some Patrick Iversen patent applications Expect most or all of these to be assigned to AVI

Q3 Results

Dr. Burger CNBC interview

Since I last wrote, a lot has happened.
1) The above mentioned references.

2) Burger's CNBC appearance, where he made an acceptable showing. It would have been a lot stronger showing, if he had made a better tie in to other viral work on-going at AVI:

The Ebola needle stick story, why did the army come to AVI when the researcher was stuck with a needle?
The Ebola data in animals and primates.
The limited human test results in West Nile Virus. The newspaper articles from Boulder and Kalamazoo suggest the drug helps.
The HCV and the data that was required to get an open label test.
The data from the MIT work on AVI's drug and flu - Avian.

3) AVI's quarterly conference call which confirms what I pointed out earlier that there was a lot of revenue compared to AVI's past. Conference Call

I had really hoped the conference call would have more clearly addressed:
a) When a drug would be ready for animal testing or at a minimum the road blocks to preparing a drug.
b) What organization would do the testing. Requirement probably: Biosafety Level 3 or Animal Biosafety Level 3 practices, procedures and facilities, plus enhancements that include special procedures, are recommended for work with the 1918 strain.
http://www.cdc.gov/flu/about/qa/1918flupandemic.htm
c) When the testing would start on animals or what the road blocks are.

If CDC/USARMIID/Walter Reed or some other US institution won't test this in a timely fashion, it would seem that one of the Asian goverments should be willing to test this.

4) The Rodman and Renshaw presentation

5) The Westgaard Conference November 21, NYC

6) The 3rd Quarter Report

7) We learned that Viopharma's VPHM results are mediocre for their HCV canidate. They will probably have to look at a combination theraphy or an alternative to salvage something. "ViroPharma and Wyeth plan to assess the antiviral activity, pharmacokinetics and tolerability of HCV-796 in combination with pegylated interferon. "

The 2.0 Log 10 reduction from baseline on day 14 was only in 17% of subjects. I think most of the patients had their maximum reduction from baseline around day 4 to day 7. Then the HCV-796 lost the ability to reduce the viral load and the load started growing. Seems like
the virus became resistant. Possibly they could increase the dose, if the safety profile allows? There is a perception the safety profile will not allow this.

From a poster on one of the message boards. "Their (VPHM) drug like all drugs in development do not address the negative strand. HCV is a positive-strand virus that serves as a template to make a negative-strand intermediate; the negative strand then serves as a template to produce multiple nascent genomes. The positve strand outnumbers the negative strand 100 to 1. The negative strand enables the virus to replicate at a prolific rate. Increasing the concentration [dose] should help but polymerases/proteases are notoriously toxic."

The door is very open for good results on Hep-C.

8) "While the study came to no conclusion on the virus's ability to move easily between people, it said the virus had developed resistance to anti-flu agents Amatadine and Rimantadine."

Of course for the latest press on AVI Biopharma please refer to their press releases.

From a poster on another message board: "I offer the following brief non-scientific description of two functions.

The first describes the action of the avii "ESPRIT" technology, (pronounced as is Esprit de Corps). This technology is at this time suited to stop mutated DNA code from hurting and even killing the human body.

The first application of this ESPRIT technology is to stop the mutation known as DMD. A very destructive type of Muscular Dystrophy, inherited from the mother of male children.

The human DNA is contained in a Nucleus which is surrounded by a Cell. Inside the Nucleus the DNA is constantly writing specific code which is known as Messenger Instructions. The ESPRIT technology is absorbed into the body, seeks out specific human cells, enters the specific targeted cell, then enters the Nucleus, waits for the DNA to begin to assemble the Messenger, and then intercepts the Mutated Code. The Messenger Instruction is then put together (excluding the mutation) and sent thru the wall of the Nucleus and becomes the RNA which then opens the healthy instruction code to all the worker bee's which then manufacture the products needed for the health of the human body.

In this instance, ESPRIT does not cure. It is a treatment which profoundly reduces the very destructive action of the disease and greatly extends the life and quality of life, of the human. This treatment must be repeated for the remainder of the victims life.

The second application of avii's technology is the virus killer.

The second application of avii's technology also seeks out and enters very specific targeted Cells, does NOT enter the Nucleus, finds the m-RNA, and stops it cold from giving any virus DNA code to the worker bee's. If a virus cannot replicate, it dies.

The above is a simple layman's description. There are others who can give a much more detailed and scientifically worded description to those who wish to explore further."

NeuGene®, ESPRIT™, Resten–MP™, and Resten–NG™ are trademarks of AVI Biopharma

I currently am long AVII stock. I also often swing trade a portion of my holdings.

I find it worthwhile to visit two message boards to learn more about AVI: http://finance.yahoo.com/q/mb?s=AVII There is a lot of noise here, but also some worthwhile info. http://groups.yahoo.com/group/thenewmorpholino/ This is a moderated message board, which must be joined, but has much more detail.

This blog is not meant to replace any resource on AVI.

This site has no relationship to AVI Biopharma.

Official AVI website: http://www.avibio.com and http://www.antivirals.com

It is solely my understanding. I bear no responsibility for the correctness or your use of the material contained within this site.
As always do your own due diligence and make your own decisions. No one knows for certain what tomorrow will bring. Only you can be responsible for your own decisions. I may hold bullish and/or bearish positions without warning and these may change without warning.

AVI Biopharma (NASDAQ: AVII)

2005-10-30T20:39:00.000-08:00

This summary is a work in progress. Thanks go to readers who added comments clarifying Hep-C and ESPRIT! I will try to blend appropriate comments into the text. Fixed - Credibility and Duchenne

AVI Biopharma (NASDAQ: AVII) has a market capitalization of $153 million as of October 28, 2005. AVI has numerous pre-clinical evaluations and a few clinical trials underway. There are five key areas AVI is addressing: Antivirals ($12-30 billion sales potential, clinical testing underway on Hepatitis-C (HCV) and preclinical on numerous viruses), Cardiovascular restenosis ($2 billion sales potential, clinical testing underway), Antitoxins ($1 billion sales potential, Homeland security, preclinical testing underway at USARMIID), Gene Therapy($.3 to ? billion), and Anticancer drugs ($2 to 5 (?) billion sales potential, preclinical on numerous cancers).

The reason a small firm like AVI is able to work on so many fronts at once, is because all the drugs are based on a common antisense platform. This enables them to produce a targeted drug in about a week after receiving the genetic makeup of the target.

If AVI can complete trials and bring one or more drugs to market with a sales potential of $1 billion, the market capitalization should rise to between 3 and 15 times sales. In other words in 3-5 years the stock could be worth 20 times what it is worth today! This is probably unrealistic: 1) AVI will have to seek more capital unless it signs a license agreement in 2006 or 2007. 2) AVI is seeking partnerships with major pharmaceuticals. Such a relationship would dilute the sales dollars from the drugs, but would bestow Wall Street credibility AVI is sadly lacking. Rich Marcy of Collectible’s LLC, an institutional research firm, said “AVI's success, just in the area of bio terror agents could easily push the stock to a $500 million to $1 billion market cap by the end of 2005.” I have heard there is a latter report by Rich Marcy, but have not seen it.

All is not rosy though! 1) AVI has a record of not meeting commitments. 2) AVI has damaged their credibility through the untimely use of PIPES for financing. One case of this was the day after Burger told Joe Kernan on CNBC that additional financing was not needed at the time, AVI announced a PIPE. A Second case of this occurred earlier this year, when in the evening after a large run up based on the announcement of a stem cell patent, AVI announced a PIPE. 3) AVI’s management has executed some very mediocre agreements in the past with Medtronic and Supergen.

A question always comes to my mind: “If AVI is so good, why hasn’t someone bought them?” I think the answer is large pharma is very content with the status quo. It is quite possible that AVI’s gene therapy will actually start curing patients rather than treating the symptoms. There is much advantage in having patients needing treatment for a life time.

Upcoming conference call - http://www.antivirals.com/pr/pr279.html On Friday November 4th, an update on the avian flu progress should be expected. I will not be surprised to hear that some agency has conducted some preliminary animal testing on Avian Flu. Additionally it would seem logical there should be an update on the enrollment in the HCV and restenosis trials.

Funding: The U.S. Senate Committee on Appropriations has approved $22 million for AVI’s R&D as part of the FY2006 defense spending bill for the continued development of technology to test for and find therapeutic agents for Ebola ($6 million), Marburg ($6 million), and dengue ($6 million) viruses, plus anthrax and ricin toxins ($4 million). This amount will likely be reduced.

AVI has received approximately $3.5 million in funding this quarter for government work. There is about $1.5 million expected FY ’05 funding in the near term. http://www.antivirals.com/pr/pr274.html

AVI will still have a loosing quarter with this injection, but $3.5 million is greater than the sum of all revenue AVI has received since 2001. And the $5 million will exceed all revenue in the last 10 years.

Technology

The NeuGene® antisense compound bind tightly to the disease-causing sequence, the genetic process is inhibited, thus disabling the pathogen or pathogenic process. This is called antisense technology because the strands of genetic material that get translated into a protein are called "sense" strands, and so "antisense" drugs are meant to stop that translation process.

Antisense compounds are made up of repeating subunits linked together to form a polymer. This is referred to as the antisense backbone. Each antisense subunit carries a genetic letter that matches with its pair on the gene target. Although genetic letters are common to all antisense compounds, the chemical structure of the subunits and the linkages that string them together vary widely.

AVI believes its NeuGene® antisense “rapid response therapeutics” have a significant role to play in the future of bioterrorism defense. NeuGene® compounds are synthetic compounds that mirror a critical portion of a disease–causing organism’s genetic code, which bind to specific portions of the target genetic sequence. Like a key in a lock, NeuGene® antisense compounds are designed to match up perfectly with a specific gene or viral sequence, blocking the function of the target gene or virus.

Other Antisense companies

Genta Inc. and ISIS Pharmaceuticals are both developing antisense drugs. A key difference between their drugs and the AVI implementation of antisense is the proprietary PMO backbone AVI uses. The neutrally charged backbone AVI, NeuGene antisense technology is based on synthetic subunits, as opposed to modified natural materials. In addition, in NeuGene technology, the linkages used to string the subunits together are uncharged molecules. These differences provide the pharmaceutical advantages required for antisense technology to achieve broad clinical utility.

Early antisense backbones were made from natural genetic materials and linkages. These compounds were easily degraded or broken down by enzymes in the blood and within cells, and had difficulty crossing cellular membranes to enter the cells that contained their genetic target.

Researchers then turned to modified backbones, designed to resist degradation by enzymes and to enter tissues and cells more efficiently. The most common of these types, second-generation antisense, use natural DNA subunits linked together by a negatively charged backbone. However, AVI scientists concluded that these early product candidates achieved minimal specificity and had ongoing safety concerns. As a result, in 1988 AVI began developing a fully synthetic backbone chemistry to enhance stability and delivery. http://www.antivirals.com/neugene.html

This neutrally charged backbone is supposed to provide advantages in stability, efficacy, specificity, delivery, and safety.

There are 2 excellent presentations at Gene-Tools, the manufactuer of research quantities of morpholinos . http://www.gene-tools.com/files/China2005NoAnimation.ppt http://files.gene-tools.com/Biocompare/ Morpholino oligos and the subunits used in their assembly are covered by multiple pending and issued US and international patents owned by AVI BioPharma (formerly ANTIVIRALS Inc.), the pioneer antisense company founded by James Summerton in 1980. Gene Tools has the exclusive worldwide license to market research quantities of Morpholino oligos. In Japan, Funakoshi Co. is the distributor of Morpholino oligos and related products. Gene-Tools also maintains a database of papers written on morpholinos. http://www.gene-tools.com/Publications

Relationships

AVI has CRADA agreements with 3 government agencies: USARMIID, Walter Reed, and Center for Disease Control. These Cooperative Research And Development Agreements provide for testing for the nastiest of viruses and toxins: Ebola, Marburg, Denegue, Ricin, and Anthrax. http://www.antivirals.com/pr/pr274.html

Antivirals single–stranded RNA viruses

HCV ms $10B 80 subjects: 40 healthy adult volunteers in the first phase of the study and 40 patients with chronic active HCV in the second phase. In the first phase, up to four dosage levels will be evaluated to confirm the safety of desired serum drug levels. In the second phase, 40 patients with chronic active HCV will be enrolled, including patients who are drug–naïve and patients who have failed conventional interferon and ribavirin treatment. http://www.antivirals.com/pr/pr272.html Standard treatment of chronic HCV hepatitis is combination therapy for 24 to 48 weeks with alpha interferon and ribavirin. This combination has limited efficacy, poor tolerability, and significant expense in terms of drug and ancillary laboratory testing. New treatment options are needed which are more efficacious, potent, less toxic, and less expensive. Phosphorodiamidate Morpholino Oligomer (PMO) synthetic chemistry compounds, as a drug class, are considered safe in humans and do not activate complement, alter clotting times, or bind to α-adrenergic receptors (which can produce hypotension) like the \ antisense compounds. One PMO, AVI-4065, has been identified as likely to inhibit all 5 genotypes of HCV based on in vitro and in vivo animal models. There are specific data that confirm that AVI-4065 can inhibit HCV RNA dependent PNA polymerase (RdRp encoded in NS5) and the HCV protease (NS3), in a non-competitive inhibitory fashion. The 50 percent Effective Concentration (EC50) is 308 nM, and the efficacy is nearly 100% at 3 μM. These data suggest that AVI-4065 is capable of inhibiting HCV protein translation in a robust manner at concentrations that should be achievable in patients. In rigorous GLP safety pharmacology and toxicity models in a variety of animal species at dosage levels up to 5 times the maximum anticipated human dosage level, inclusive of non-human primates, AVI-4065 is considered safe. These trials are being conducted at Veterans Affairs Palo Alto Health Care System, Palo Alto, California and Alpine Clinical Research Center, Inc., Boulder, Colorado. Mark Holodniy, M.D., Principal Investigator, Stanford University School of Medicine and Department of Veterans Affairs Public is the principal investigator. http://www.clinicaltrials.gov/ct/show/NCT00229749?order=2 These trials may have started in September. AVI expects to have not only safety and pharmacokinetics, but also early indications of efficacy data by the end of the year. http://www.antivirals.com/pr/pr270.html

Influenza, Avian flu

targeting the Influenza A (flu) virus. AVI has targeted genetic regions of the virus that are highly conserved between six viral subtypes that cause human disease. These include three subtypes that caused pandemics in the 20th century — the 1918 Spanish flu (H1N1), the 1957 Asian flu (H2N2) and the 1968 Hong Kong flu (H3N2) — and three subtypes of avian flu that have been reported to cause disease in man (H5N1, H7N7 and H9N2).

“Several of these NeuGene® compounds have been efficacious in early experiments and should now be considered for in vivo evaluation against H1N1 and H5N1,” In initial experiments, eight NeuGene® antisense compounds were developed to target regions of the influenza virus genome believed to be critical to virus survival. AVI also selected regions of the virus that are highly conserved across all six virus subtypes that cause human disease. These candidates have been tested in various viral culture assays with several collaborators, including Professor J. Chen and Quing Ge at the Massachusetts Institute of Technology. Several agents that were both potent and specific for Influenza A have been identified as suppressing replication of H1N1. One agent was found to inhibit both viral transcription and replication. Moreover, combinations of two agents were routinely twofold to threefold more active than single agents alone, and one combination of two agents exhibited sevenfold to eightfold improvement in viral reduction compared with a single agent.

Additional experiments showed that a single mismatch within the targeted region of the virus caused less than a 10 percent loss of activity of the drug. This provides strong evidence that a single NeuGene® antisense drug could potentially shut down all the flu virus subtypes, including the H5N1 avian flu, even if a mutation occurred in these highly conserved regions. http://www.antivirals.com/pr/pr277.html The World Health Organization (WHO) said recent isolates of the H5N1 virus from birds and humans in Asia show slight genetic changes from the isolate on which current experimental H5N1 vaccines are based. http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/oct2805chiron.html This suggests the vaccines may not be effective when H5N1 mutates into a virus that is effective at Human to Human transmission.

Transcription - The process by which messenger RNA is synthesized from a DNA template resulting in the transfer of genetic information from the DNA molecule to the messenger RNA. http://www.answers.com/main/ntquery;jsessionid=fi3v55p0d29s?tname=transcription-genetics&method=6&sbid=lc02b

Replication – The more effective process where a cell spreads by division. http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=DNA+replication&amp;amp;amp;gwp=8&curtab=2222_1&linktext=DNA%20replication

Ebola

At U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, Md studies provided evidence of robust efficacy in multiple experiments conducted on mice, guinea pigs and nonhuman primates. The most effective protocols, where 100 percent survival was observed at low doses of drug, were three–drug combinations targeting different Ebola genes when administered 24–48 hours after virus. A three–drug combination was successful in the initial nonhuman primate studies challenge. It has been long rumored and awaited that Sina Bavari, Ph.D., chief of immunology, target identification, and translational research, USAMRIID will have an article published with these results. The disease is a National Institute of Allergy and Infectious Disease (NIAID) priority A pathogen and a bioterrorism suspect agent of interest to the Department of Defense and Project BioShield. There are currently no approved treatments for Ebola. Commentary: The beauty of the ebola treatment is it may open the door to government stockpiling without the lengthy FDA approval process. Ebola is spreading at 50km per year in Africa. http://www.antivirals.com/pr/pr275.html USAMRIID and AVI went into Rhesus monkeys and took a very aggressive dosing stance because this is a very large hurdle. And with a very aggressive dosing stance, we were able to achieve survival in 75% of the animals. http://www.antivirals.com/pr/pr270.html At a presentation which seems to be no longer accessible, it was reported that the one monkey that died had complications that are probably unrelated to the Ebola or the antisense drug.

Marburg

In animals challenged with high doses of the virus that were nearly 100 percent lethal in untreated animals, a high survival rate was observed in single agent protocols targeting distinct Marburg genes. The most recent outbreak of Marburg virus started in October 2004 in Angola. According to the World Health Organization (WHO), as of Aug. 23, 2005, the Ministry of Health (MOH) of Angola had reported a total of 374 cases of Marburg hemorrhagic fever with 329 fatalities. http://www.antivirals.com/pr/pr275.html

Denegue

November edition of the Journal of Virology, is titled “Inhibition of dengue virus translation and RNA synthesis by a morpholino oligomer targeted to the top of the terminal 3’ stem–loop structure.” AVI’s NeuGene® antisense agent inhibited each of the four serotypes of dengue virus. http://www.antivirals.com/pr/pr278.html Dr. Richard Kinny of the Division of Vector–Borne Infectious Diseases of the Centers for Disease Control provided an update on the ongoing collaborative dengue virus investigation between AVI and the CDC, demonstrating our NeuGene®’s ability to extend the lives of dengue–virus–infected mice in a statistically significant manner. http://www.antivirals.com/pr/pr270.html http://www.antivirals.com/pr/pr278.html

Common Cold - Dr. Rene Rijnbrand discussed how NeuGene® antisense drugs inhibit a virus known to cause a large percentage of the incidence of the common cold. The studies also identified broader potential applications to a larger group of viruses called enteroviruses, which infect 10 to 15 million people in the U.S. each year. http://www.antivirals.com/pr/pr267.html

West Nile Virus based on a few tests under IND’s AVI-4020 appears to help victims with neuroinvasive WNV. These victims were treated at Boulder Colorado and Kalamazoo Michigan. There is a trial that is open at Barrow Neurologic Institute - St. Joseph's Hospital and Medical Center, Phoenix, Arizona and Boulder Community Hospital, Boulder, Colorado, but there are no reported enrollments. http://www.clinicaltrials.gov/ct/show/NCT00091845?order=1

SARS coronavirus

These studies were conducted at The Scripps Research Institute (TSRI) in La Jolla, Calif. The article was published in the August 2005 Journal of Virology and will be available online at http://jvi.asm.org/current.dtl.

“This is one of the most comprehensive evaluations of a NeuGene antisense antiviral drug ever published,” said Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI. “These data emphasize the robust antiviral potential of our antisense drugs, which demonstrates again that our NeuGene antisense agents are highly promising as therapies to treat not only SARS coronavirus, but also a variety of other viruses.”

The experiments outlined in the paper demonstrate that SARS-CoV develops resistance to NeuGene antisense only after multiple mutations in the viral genome, showing that the NeuGene agent is less susceptible to viral escape than small molecule drugs. Further, the fact that the resistant mutations occurred only at the NeuGene binding site verifies the antisense mechanism of action. http://www.antivirals.com/pr/pr266.html

Other
Rift Valley Fever

Cardiovascular – Restenosis ms $2B

The delivery of the antisense drug Resten MP or NG to the site of the injury caused by the stent will slow or prevent the regrowth in the area of the stent which will cause future blockage of the vessel.

On September 20, 2005 AVI reported initiation of patient enrollment in Germany for the company’s APPRAISAL Phase II clinical study. The APPRAISAL trial is designed to evaluate AVI’s Resten–MP™ in the prevention of cardiovascular restenosis when delivered intravenously in conjunction with the placement of one or more bare–metal stents. The binary restenosis rate was reduced by 75 percent among patients who received a therapeutic dose. “AVI is also conducting a Phase II clinical study with Resten–MP delivered intravenously at the University of Nebraska Medical Center in combination with the Taxus stent,” said Denis R. Burger, Ph.D., chief executive officer of AVI. Donald Cutlip, M.D., chief medical officer at Harvard Clinical Research Institute, said, “ If Resten–MP can significantly reduce late lumen loss at six months compared to the historical control, there is every confidence that pivotal studies would demonstrate the therapeutic value of the drug.” http://www.antivirals.com/pr/pr271.html

Dr. Raimund Erbel will present “Microbubble Delivery of C–MYC Antisense After Coronary Stents: Concept, Experimental Results, and Preliminary Findings From an FIM Trial” http://www.antivirals.com/pr/pr276.html AVII has chosen not to share any of the information presented on the preliminary findings in the First In Man trials or experimental results.

Dr. Nicholas Kipshidze will present “Nanoparticle Delivery of Antirestenotic Drugs: Insights From Preclinical Studies” http://www.antivirals.com/pr/pr276.html Found to compare favorably with two other routes of administration — catheter and stent — in preventing cardiovascular restenosis following balloon angioplasty in animal models.

AVII is working on a non polymer coated DES. This appears to be a longer term approach. Resten–NG® program on drug eluding stents. AVI is finishing development work on their DES System and are currently initiating confirmatory pig studies before moving into human trials to receive CE Mark approval in Europe. http://www.antivirals.com/pr/pr270.html

Gene Therapy

Duchenne Muscular Dystrophy – ESPRIT™ (Exon Skipping Pre–RNA Interference Technology). ESPRIT( pronounced as in "ESPRIT DE CORPS") therapeutics are designed to either delete disease–causing genetic sequences or skip functional sequences to redesign proteins that are over–expressed or harmful in certain diseases. Dr. Wilton has used the mdx mouse model of muscular dystrophy to show that the early stop signal in exon 23 can be efficiently skipped in the modified mRNA so that significant amounts of dystrophin are produced and correctly localized. The efficient delivery of some of these compounds generated very promising results with near–normal dystrophin being produced and persisting for months from a single treatment. This is not a cure, but a treatment requiring future treatments. Therefore the revenue stream will be recurring . Between 50,000 and 250,000 individuals are affected annually by MD. http://www.antivirals.com/pr/pr273.html

This is not Gene Replacement, nor does it change the basic behavior of the Gene itself. It does change the instructions the Gene issues to the RNA, by omitting the harmfull portion of the sequence, the genetic mutation code.

A very interesting presentation on the topic of DMD is: http://www.parentprojectmd.org/ppmd/conference/pdfs2005/2005_akkari_morpholino.pdf
The interesting question to be answered after reviewing this presentation is, "What is the relationship between GlaxoSmithKline and AVI?" It is very clear the GSK work is almost certainly based on AVI patents.

Other - ESPRIT therapeutics allow for fine genetic surgery at the RNA processing level, providing a new and very potent tool for altering many disease mechanisms. In addition to genetic disorders such as muscular dystrophy, AVI is now applying the ESPRIT therapeutic approach to diseases with an immunologic component, such as diabetes and multiple sclerosis. http://www.antivirals.com/pr/pr273.html

Cancer

Bladder $1B

Prostrate - In early June, results from two preclinical cancer studies were presented at the Annual Meeting of the Endocrine Society. The first study, which was sponsored in part by the National Cancer Institute, demonstrates the ability of AVI’s NeuGene® antisense technology to down regulate the androgen receptor, which plays a pivotal role in the growth and proliferation of prostate cancer. http://www.antivirals.com/pr/pr261.html

Ovarian - The other preclinical study in ovarian cancer, conducted in collaboration with scientists at Oregon State University, builds on AVI’s previous experience targeting the XIAP gene. This gene has been found to protect cancer cells from the affects of radiation. Our NeuGene® negated the radiation resistance brought on by the XAIP gene, thereby giving the cancer cells enhanced susceptibility to radiation therapy. http://www.antivirals.com/pr/pr261.html http://www.antivirals.com/pr/pr270.html

Pancreatic/Colorectal – Avicine – This appears dead!

Antitoxins - interrupt the cellular mechanism that some toxins employ to induce lethal toxicity

Ricin - In cell culture studies, where ricin was 100 percent lethal, greater than 75 percent cellular viability was achieved with antisense targeting the ricin binding site on ribosomal RNA. http://www.antivirals.com/pr/pr275.html

Anthrax - Preliminary survival experiments in mice showed that almost all antisense–treated mice survived a lethal challenge with anthrax spores. http://www.antivirals.com/pr/pr275.html

Safety

AVI’s NeuGene® antisense platform has a well–defined safety record in human clinical trials. Approximately 250 patients have been dosed with NeuGene® drug candidates targeting host and viral gene targets in 11 clinical studies under multiple INDs. Five different routes of administration have been employed in AVI’s clinical studies, and doses up to 450 mg have been administered without a single drug–related, serious adverse event. http://www.antivirals.com/pr/pr277.html